TW517063B - Biotin derivatives - Google Patents
Biotin derivatives Download PDFInfo
- Publication number
- TW517063B TW517063B TW085108686A TW85108686A TW517063B TW 517063 B TW517063 B TW 517063B TW 085108686 A TW085108686 A TW 085108686A TW 85108686 A TW85108686 A TW 85108686A TW 517063 B TW517063 B TW 517063B
- Authority
- TW
- Taiwan
- Prior art keywords
- gly
- fmoc
- asp
- lys
- arg
- Prior art date
Links
- 125000004057 biotinyl group Chemical class [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 title description 3
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 108010044426 integrins Proteins 0.000 claims abstract description 14
- 102000006495 integrins Human genes 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 206010003210 Arteriosclerosis Diseases 0.000 claims abstract description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 claims abstract description 5
- 208000035475 disorder Diseases 0.000 claims abstract description 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 4
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 4
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 4
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 3
- 229910052770 Uranium Inorganic materials 0.000 claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims description 71
- 238000006243 chemical reaction Methods 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 16
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 claims description 12
- 125000001931 aliphatic group Chemical group 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 102000008946 Fibrinogen Human genes 0.000 claims description 10
- 108010049003 Fibrinogen Proteins 0.000 claims description 10
- 229940012952 fibrinogen Drugs 0.000 claims description 10
- 239000003446 ligand Substances 0.000 claims description 9
- 108090001008 Avidin Proteins 0.000 claims description 7
- 150000001412 amines Chemical class 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 7
- 230000003993 interaction Effects 0.000 claims description 7
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims description 3
- 229940125798 integrin inhibitor Drugs 0.000 claims description 3
- 238000000386 microscopy Methods 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 2
- 238000001042 affinity chromatography Methods 0.000 claims description 2
- 230000001745 anti-biotin effect Effects 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 15
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 9
- 239000004202 carbamide Substances 0.000 claims 9
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 claims 6
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 claims 5
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000003544 oxime group Chemical group 0.000 claims 2
- 210000002826 placenta Anatomy 0.000 claims 2
- JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 claims 2
- ZRVZOBGMZWVJOS-VMXHOPILSA-N (2s)-6-amino-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)CN ZRVZOBGMZWVJOS-VMXHOPILSA-N 0.000 claims 1
- XIWRCSVXKPGGAJ-UHFFFAOYSA-N 1-(5-tert-butyl-2-phenylpyrazol-3-yl)-3-(4-chlorophenyl)urea Chemical compound C=1C=CC=CC=1N1N=C(C(C)(C)C)C=C1NC(=O)NC1=CC=C(Cl)C=C1 XIWRCSVXKPGGAJ-UHFFFAOYSA-N 0.000 claims 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims 1
- 241000219112 Cucumis Species 0.000 claims 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 claims 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 claims 1
- GBBDVMJBRZSBRW-UHFFFAOYSA-N OC=O.CCOC(N)=O Chemical compound OC=O.CCOC(N)=O GBBDVMJBRZSBRW-UHFFFAOYSA-N 0.000 claims 1
- 102000015439 Phospholipases Human genes 0.000 claims 1
- 108010064785 Phospholipases Proteins 0.000 claims 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 230000000052 comparative effect Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 108010064365 glycyl- arginyl-glycyl-aspartyl-seryl-prolyl-lysine Proteins 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 230000001624 sedative effect Effects 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 abstract description 16
- 229960002685 biotin Drugs 0.000 abstract description 8
- 235000020958 biotin Nutrition 0.000 abstract description 8
- 239000011616 biotin Substances 0.000 abstract description 8
- 238000011282 treatment Methods 0.000 abstract description 6
- 239000003112 inhibitor Substances 0.000 abstract description 5
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 abstract description 4
- 230000002491 angiogenic effect Effects 0.000 abstract 1
- 150000001615 biotins Chemical class 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- -1 biotin compound Chemical class 0.000 description 68
- ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 57
- KLBPUVPNPAJWHZ-UMSFTDKQSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-tritylsulfanylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)SC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KLBPUVPNPAJWHZ-UMSFTDKQSA-N 0.000 description 56
- FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 description 53
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 48
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 45
- 125000006239 protecting group Chemical group 0.000 description 37
- DVBUCBXGDWWXNY-SFHVURJKSA-N (2s)-5-(diaminomethylideneamino)-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C3=CC=CC=C3C2=C1 DVBUCBXGDWWXNY-SFHVURJKSA-N 0.000 description 35
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 33
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 31
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 25
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 24
- 230000002079 cooperative effect Effects 0.000 description 24
- XXMYDXUIZKNHDT-QNGWXLTQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1-tritylimidazol-4-yl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(N=C1)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXMYDXUIZKNHDT-QNGWXLTQSA-N 0.000 description 22
- KJYAFJQCGPUXJY-UMSFTDKQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-oxo-4-(tritylamino)butanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KJYAFJQCGPUXJY-UMSFTDKQSA-N 0.000 description 22
- 239000011347 resin Substances 0.000 description 19
- 229920005989 resin Polymers 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000002253 acid Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 14
- 239000013543 active substance Substances 0.000 description 13
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 10
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 229960002317 succinimide Drugs 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 7
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 229910001868 water Inorganic materials 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 238000007327 hydrogenolysis reaction Methods 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- WQVYAWIMAWTGMW-ZLUOBGJFSA-N Ala-Asp-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N WQVYAWIMAWTGMW-ZLUOBGJFSA-N 0.000 description 4
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000012442 inert solvent Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000010532 solid phase synthesis reaction Methods 0.000 description 4
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- XFZJGFIKQCCLGK-UHFFFAOYSA-M 1,1-dimethyl-4-phenylpiperazinium iodide Chemical compound [I-].C1C[N+](C)(C)CCN1C1=CC=CC=C1 XFZJGFIKQCCLGK-UHFFFAOYSA-M 0.000 description 3
- ZPGDWQNBZYOZTI-UHFFFAOYSA-N 1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)C1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- AOLHUMAVONBBEZ-STQMWFEESA-N Tyr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AOLHUMAVONBBEZ-STQMWFEESA-N 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 229960004592 isopropanol Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 239000000052 vinegar Substances 0.000 description 3
- 235000021419 vinegar Nutrition 0.000 description 3
- WDGICUODAOGOMO-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-DHUJRADRSA-N 0.000 description 2
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
- PGLFPEYYIQQJOP-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O.NCCCCCC(O)=O PGLFPEYYIQQJOP-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- XAEWTDMGFGHWFK-IMJSIDKUSA-N Ala-Asp Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O XAEWTDMGFGHWFK-IMJSIDKUSA-N 0.000 description 2
- NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 2
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FKBFDTRILNZGAI-IMJSIDKUSA-N Asp-Cys Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(O)=O FKBFDTRILNZGAI-IMJSIDKUSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 108010012088 Fibrinogen Receptors Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ULEBESPCVWBNIF-BYPYZUCNSA-N L-arginine amide Chemical compound NC(=O)[C@@H](N)CCCNC(N)=N ULEBESPCVWBNIF-BYPYZUCNSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- HGNRJCINZYHNOU-LURJTMIESA-N Lys-Gly Chemical compound NCCCC[C@H](N)C(=O)NCC(O)=O HGNRJCINZYHNOU-LURJTMIESA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- MIDZLCFIAINOQN-WPRPVWTQSA-N Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 MIDZLCFIAINOQN-WPRPVWTQSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- HMNSRTLZAJHSIK-YUMQZZPRSA-N Pro-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 HMNSRTLZAJHSIK-YUMQZZPRSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- NJEMRSFGDNECGF-GCJQMDKQSA-N Thr-Ala-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O NJEMRSFGDNECGF-GCJQMDKQSA-N 0.000 description 2
- NLKUJNGEGZDXGO-XVKPBYJWSA-N Tyr-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NLKUJNGEGZDXGO-XVKPBYJWSA-N 0.000 description 2
- QZOSVNLXLSNHQK-UWVGGRQHSA-N Tyr-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 QZOSVNLXLSNHQK-UWVGGRQHSA-N 0.000 description 2
- WJKJJGXZRHDNTN-UWVGGRQHSA-N Tyr-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 WJKJJGXZRHDNTN-UWVGGRQHSA-N 0.000 description 2
- HPYDSVWYXXKHRD-VIFPVBQESA-N Tyr-Gly Chemical compound [O-]C(=O)CNC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 HPYDSVWYXXKHRD-VIFPVBQESA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 108010041407 alanylaspartic acid Proteins 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- ZVDPYSVOZFINEE-BQBZGAKWSA-N alpha-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O ZVDPYSVOZFINEE-BQBZGAKWSA-N 0.000 description 2
- 125000006242 amine protecting group Chemical group 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 2
- 108010057412 arginyl-glycyl-aspartyl-phenylalanine Proteins 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical class CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 108010064235 lysylglycine Proteins 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 150000004965 peroxy acids Chemical class 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 108010024607 phenylalanylalanine Proteins 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 108010004914 prolylarginine Proteins 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- QXVFEIPAZSXRGM-DJJJIMSYSA-N (2s,3s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@@H](C)CC)C(O)=O)C3=CC=CC=C3C2=C1 QXVFEIPAZSXRGM-DJJJIMSYSA-N 0.000 description 1
- ARNGIGOPGOEJCH-KKUMJFAQSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-phenylethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ARNGIGOPGOEJCH-KKUMJFAQSA-N 0.000 description 1
- UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- YMVOQWLZDQQYNQ-UHFFFAOYSA-N 1,5-diphenoxypentan-3-one Chemical compound C=1C=CC=CC=1OCCC(=O)CCOC1=CC=CC=C1 YMVOQWLZDQQYNQ-UHFFFAOYSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical class CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical group COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- WNYJVAMZRBTOPE-YVSFHVDLSA-N 2-[(2s,5r,8r,11s)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-8-(sulfanylmethyl)-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)NC(=O)[C@H]1CC1=CC=CC=C1 WNYJVAMZRBTOPE-YVSFHVDLSA-N 0.000 description 1
- WOJJIRYPFAZEPF-YFKPBYRVSA-N 2-[[(2s)-2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]propanoyl]amino]acetate Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)CN WOJJIRYPFAZEPF-YFKPBYRVSA-N 0.000 description 1
- QMOQBVOBWVNSNO-UHFFFAOYSA-N 2-[[2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]acetyl]amino]acetate Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(O)=O QMOQBVOBWVNSNO-UHFFFAOYSA-N 0.000 description 1
- FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 description 1
- PECYZEOJVXMISF-UWTATZPHSA-N 3-amino-D-alanine Chemical compound NC[C@@H](N)C(O)=O PECYZEOJVXMISF-UWTATZPHSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
- LLQHSBBZNDXTIV-UHFFFAOYSA-N 6-[5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC1CC(=NO1)C1=CC2=C(NC(O2)=O)C=C1 LLQHSBBZNDXTIV-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- DKJPOZOEBONHFS-ZLUOBGJFSA-N Ala-Ala-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O DKJPOZOEBONHFS-ZLUOBGJFSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- GFGUPLIETCNQGF-DCAQKATOSA-N Asn-Pro-His Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC(=O)N)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O GFGUPLIETCNQGF-DCAQKATOSA-N 0.000 description 1
- DVUFTQLHHHJEMK-IMJSIDKUSA-N Asp-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O DVUFTQLHHHJEMK-IMJSIDKUSA-N 0.000 description 1
- VPPXTHJNTYDNFJ-CIUDSAMLSA-N Asp-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N VPPXTHJNTYDNFJ-CIUDSAMLSA-N 0.000 description 1
- PSZNHSNIGMJYOZ-WDSKDSINSA-N Asp-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PSZNHSNIGMJYOZ-WDSKDSINSA-N 0.000 description 1
- VGRHZPNRCLAHQA-IMJSIDKUSA-N Asp-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O VGRHZPNRCLAHQA-IMJSIDKUSA-N 0.000 description 1
- FRYULLIZUDQONW-IMJSIDKUSA-N Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FRYULLIZUDQONW-IMJSIDKUSA-N 0.000 description 1
- CKAJHWFHHFSCDT-WHFBIAKZSA-N Asp-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O CKAJHWFHHFSCDT-WHFBIAKZSA-N 0.000 description 1
- JHFNSBBHKSZXKB-VKHMYHEASA-N Asp-Gly Chemical compound OC(=O)C[C@H](N)C(=O)NCC(O)=O JHFNSBBHKSZXKB-VKHMYHEASA-N 0.000 description 1
- PZXPWHFYZXTFBI-YUMQZZPRSA-N Asp-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PZXPWHFYZXTFBI-YUMQZZPRSA-N 0.000 description 1
- BSWHERGFUNMWGS-UHFFFAOYSA-N Asp-Ile Chemical compound CCC(C)C(C(O)=O)NC(=O)C(N)CC(O)=O BSWHERGFUNMWGS-UHFFFAOYSA-N 0.000 description 1
- OAMLVOVXNKILLQ-BQBZGAKWSA-N Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O OAMLVOVXNKILLQ-BQBZGAKWSA-N 0.000 description 1
- DYDKXJWQCIVTMR-WDSKDSINSA-N Asp-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O DYDKXJWQCIVTMR-WDSKDSINSA-N 0.000 description 1
- YZQCXOFQZKCETR-UWVGGRQHSA-N Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YZQCXOFQZKCETR-UWVGGRQHSA-N 0.000 description 1
- UKGGPJNBONZZCM-WDSKDSINSA-N Asp-Pro Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O UKGGPJNBONZZCM-WDSKDSINSA-N 0.000 description 1
- UAXIKORUDGGIGA-DCAQKATOSA-N Asp-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC(=O)O)N)C(=O)N[C@@H](CCCCN)C(=O)O UAXIKORUDGGIGA-DCAQKATOSA-N 0.000 description 1
- NTQDELBZOMWXRS-IWGUZYHVSA-N Asp-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O NTQDELBZOMWXRS-IWGUZYHVSA-N 0.000 description 1
- ZARXTZFGQZBYFO-JQWIXIFHSA-N Asp-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC(O)=O)N)C(O)=O)=CNC2=C1 ZARXTZFGQZBYFO-JQWIXIFHSA-N 0.000 description 1
- NALWOULWGHTVDA-UWVGGRQHSA-N Asp-Tyr Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NALWOULWGHTVDA-UWVGGRQHSA-N 0.000 description 1
- CPMKYMGGYUFOHS-FSPLSTOPSA-N Asp-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O CPMKYMGGYUFOHS-FSPLSTOPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 101000981883 Brevibacillus parabrevis ATP-dependent tryptophan/phenylalanine/tyrosine adenylase Proteins 0.000 description 1
- 101000981889 Brevibacillus parabrevis Linear gramicidin-PCP reductase Proteins 0.000 description 1
- 101100292586 Caenorhabditis elegans mtr-4 gene Proteins 0.000 description 1
- 101100459438 Caenorhabditis elegans nac-1 gene Proteins 0.000 description 1
- 101100079984 Caenorhabditis elegans nhr-9 gene Proteins 0.000 description 1
- 101000906861 Chondromyces crocatus ATP-dependent tyrosine adenylase Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 101100129232 Danio rerio mafaa gene Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- SCCPDJAQCXWPTF-VKHMYHEASA-N Gly-Asp Chemical compound NCC(=O)N[C@H](C(O)=O)CC(O)=O SCCPDJAQCXWPTF-VKHMYHEASA-N 0.000 description 1
- GGLIDLCEPDHEJO-BQBZGAKWSA-N Gly-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CN GGLIDLCEPDHEJO-BQBZGAKWSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- QOOWRKBDDXQRHC-BQBZGAKWSA-N L-lysyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN QOOWRKBDDXQRHC-BQBZGAKWSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 description 1
- ITWQLSZTLBKWJM-YUMQZZPRSA-N Lys-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCCCN ITWQLSZTLBKWJM-YUMQZZPRSA-N 0.000 description 1
- ZOKVLMBYDSIDKG-CSMHCCOUSA-N Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ZOKVLMBYDSIDKG-CSMHCCOUSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- LDNOWZOWQPKCKK-UHFFFAOYSA-N OO.[Na].[Na] Chemical compound OO.[Na].[Na] LDNOWZOWQPKCKK-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- ULECEJGNDHWSKD-QEJZJMRPSA-N Phe-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 ULECEJGNDHWSKD-QEJZJMRPSA-N 0.000 description 1
- OZILORBBPKKGRI-RYUDHWBXSA-N Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 OZILORBBPKKGRI-RYUDHWBXSA-N 0.000 description 1
- HWMGTNOVUDIKRE-UWVGGRQHSA-N Phe-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 HWMGTNOVUDIKRE-UWVGGRQHSA-N 0.000 description 1
- KNPVDQMEHSCAGX-UWVGGRQHSA-N Phe-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KNPVDQMEHSCAGX-UWVGGRQHSA-N 0.000 description 1
- GLUBLISJVJFHQS-VIFPVBQESA-N Phe-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 GLUBLISJVJFHQS-VIFPVBQESA-N 0.000 description 1
- JJHVFCUWLSKADD-ONGXEEELSA-N Phe-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O JJHVFCUWLSKADD-ONGXEEELSA-N 0.000 description 1
- NAXPHWZXEXNDIW-JTQLQIEISA-N Phe-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 NAXPHWZXEXNDIW-JTQLQIEISA-N 0.000 description 1
- OHUXOEXBXPZKPT-STQMWFEESA-N Phe-His Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)C1=CC=CC=C1 OHUXOEXBXPZKPT-STQMWFEESA-N 0.000 description 1
- WEMYTDDMDBLPMI-DKIMLUQUSA-N Phe-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N WEMYTDDMDBLPMI-DKIMLUQUSA-N 0.000 description 1
- RFCVXVPWSPOMFJ-STQMWFEESA-N Phe-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 RFCVXVPWSPOMFJ-STQMWFEESA-N 0.000 description 1
- AUJWXNGCAQWLEI-KBPBESRZSA-N Phe-Lys-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O AUJWXNGCAQWLEI-KBPBESRZSA-N 0.000 description 1
- PYOHODCEOHCZBM-RYUDHWBXSA-N Phe-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 PYOHODCEOHCZBM-RYUDHWBXSA-N 0.000 description 1
- GKZIWHRNKRBEOH-HOTGVXAUSA-N Phe-Phe Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)C1=CC=CC=C1 GKZIWHRNKRBEOH-HOTGVXAUSA-N 0.000 description 1
- ZVRJWDUPIDMHDN-ULQDDVLXSA-N Phe-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 ZVRJWDUPIDMHDN-ULQDDVLXSA-N 0.000 description 1
- ROHDXJUFQVRDAV-UWVGGRQHSA-N Phe-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 ROHDXJUFQVRDAV-UWVGGRQHSA-N 0.000 description 1
- NYQBYASWHVRESG-MIMYLULJSA-N Phe-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 NYQBYASWHVRESG-MIMYLULJSA-N 0.000 description 1
- JMCOUWKXLXDERB-WMZOPIPTSA-N Phe-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=CC=C1 JMCOUWKXLXDERB-WMZOPIPTSA-N 0.000 description 1
- FSXRLASFHBWESK-HOTGVXAUSA-N Phe-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 FSXRLASFHBWESK-HOTGVXAUSA-N 0.000 description 1
- RGMLUHANLDVMPB-ULQDDVLXSA-N Phe-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N RGMLUHANLDVMPB-ULQDDVLXSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OCSACVPBMIYNJE-GUBZILKMSA-N Pro-Arg-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O OCSACVPBMIYNJE-GUBZILKMSA-N 0.000 description 1
- BAKAHWWRCCUDAF-IHRRRGAJSA-N Pro-His-Lys Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H]1NCCC1)C1=CN=CN1 BAKAHWWRCCUDAF-IHRRRGAJSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical group [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- LVVBAKCGXXUHFO-ZLUOBGJFSA-N Ser-Ala-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O LVVBAKCGXXUHFO-ZLUOBGJFSA-N 0.000 description 1
- WSTIOCFMWXNOCX-YUMQZZPRSA-N Ser-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N WSTIOCFMWXNOCX-YUMQZZPRSA-N 0.000 description 1
- JIPVNVNKXJLFJF-BJDJZHNGSA-N Ser-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N JIPVNVNKXJLFJF-BJDJZHNGSA-N 0.000 description 1
- NFDYGNFETJVMSE-BQBZGAKWSA-N Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CO NFDYGNFETJVMSE-BQBZGAKWSA-N 0.000 description 1
- UBRMZSHOOIVJPW-SRVKXCTJSA-N Ser-Leu-Lys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UBRMZSHOOIVJPW-SRVKXCTJSA-N 0.000 description 1
- WBAXJMCUFIXCNI-WDSKDSINSA-N Ser-Pro Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WBAXJMCUFIXCNI-WDSKDSINSA-N 0.000 description 1
- ADJDNJCSPNFFPI-FXQIFTODSA-N Ser-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO ADJDNJCSPNFFPI-FXQIFTODSA-N 0.000 description 1
- NMZXJDSKEGFDLJ-DCAQKATOSA-N Ser-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CO)N)C(=O)N[C@@H](CCCCN)C(=O)O NMZXJDSKEGFDLJ-DCAQKATOSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- OHGNSVACHBZKSS-KWQFWETISA-N Trp-Ala Chemical compound C1=CC=C2C(C[C@H]([NH3+])C(=O)N[C@@H](C)C([O-])=O)=CNC2=C1 OHGNSVACHBZKSS-KWQFWETISA-N 0.000 description 1
- HYVLNORXQGKONN-NUTKFTJISA-N Trp-Ala-Lys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 HYVLNORXQGKONN-NUTKFTJISA-N 0.000 description 1
- GRQCSEWEPIHLBI-JQWIXIFHSA-N Trp-Asn Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O)=CNC2=C1 GRQCSEWEPIHLBI-JQWIXIFHSA-N 0.000 description 1
- PEEAINPHPNDNGE-JQWIXIFHSA-N Trp-Asp Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O)=CNC2=C1 PEEAINPHPNDNGE-JQWIXIFHSA-N 0.000 description 1
- SMDQRGAERNMJJF-JQWIXIFHSA-N Trp-Cys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CS)C(O)=O)=CNC2=C1 SMDQRGAERNMJJF-JQWIXIFHSA-N 0.000 description 1
- PWIQCLSQVQBOQV-AAEUAGOBSA-N Trp-Glu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CNC2=C1 PWIQCLSQVQBOQV-AAEUAGOBSA-N 0.000 description 1
- WLBZWXXGSOLJBA-HOCLYGCPSA-N Trp-Gly-Lys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 WLBZWXXGSOLJBA-HOCLYGCPSA-N 0.000 description 1
- LYMVXFSTACVOLP-ZFWWWQNUSA-N Trp-Leu Chemical compound C1=CC=C2C(C[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C([O-])=O)=CNC2=C1 LYMVXFSTACVOLP-ZFWWWQNUSA-N 0.000 description 1
- CXPJPTFWKXNDKV-NUTKFTJISA-N Trp-Leu-Ala Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O)=CNC2=C1 CXPJPTFWKXNDKV-NUTKFTJISA-N 0.000 description 1
- RRVUOLRWIZXBRQ-IHPCNDPISA-N Trp-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N RRVUOLRWIZXBRQ-IHPCNDPISA-N 0.000 description 1
- DXYQIGZZWYBXSD-JSGCOSHPSA-N Trp-Pro Chemical compound O=C([C@H](CC=1C2=CC=CC=C2NC=1)N)N1CCC[C@H]1C(O)=O DXYQIGZZWYBXSD-JSGCOSHPSA-N 0.000 description 1
- XDQGKIMTRSVSBC-WDSOQIARSA-N Trp-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CNC2=CC=CC=C12 XDQGKIMTRSVSBC-WDSOQIARSA-N 0.000 description 1
- MYVYPSWUSKCCHG-JQWIXIFHSA-N Trp-Ser Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CO)C(O)=O)=CNC2=C1 MYVYPSWUSKCCHG-JQWIXIFHSA-N 0.000 description 1
- YBRHKUNWEYBZGT-WLTAIBSBSA-N Trp-Thr Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(O)=O)=CNC2=C1 YBRHKUNWEYBZGT-WLTAIBSBSA-N 0.000 description 1
- NQIHMZLGCZNZBN-PXNSSMCTSA-N Trp-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)N)C(O)=O)=CNC2=C1 NQIHMZLGCZNZBN-PXNSSMCTSA-N 0.000 description 1
- TYYLDKGBCJGJGW-WMZOPIPTSA-N Trp-Tyr Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(O)=O)C1=CC=C(O)C=C1 TYYLDKGBCJGJGW-WMZOPIPTSA-N 0.000 description 1
- LWFWZRANSFAJDR-JSGCOSHPSA-N Trp-Val Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(O)=O)=CNC2=C1 LWFWZRANSFAJDR-JSGCOSHPSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- ZWZOCUWOXSDYFZ-CQDKDKBSSA-N Tyr-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 ZWZOCUWOXSDYFZ-CQDKDKBSSA-N 0.000 description 1
- JXNRXNCCROJZFB-RYUDHWBXSA-N Tyr-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JXNRXNCCROJZFB-RYUDHWBXSA-N 0.000 description 1
- ONWMQORSVZYVNH-UWVGGRQHSA-N Tyr-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 ONWMQORSVZYVNH-UWVGGRQHSA-N 0.000 description 1
- UBAQSAUDKMIEQZ-QWRGUYRKSA-N Tyr-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 UBAQSAUDKMIEQZ-QWRGUYRKSA-N 0.000 description 1
- PDSLRCZINIDLMU-QWRGUYRKSA-N Tyr-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PDSLRCZINIDLMU-QWRGUYRKSA-N 0.000 description 1
- CNLKDWSAORJEMW-KWQFWETISA-N Tyr-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O CNLKDWSAORJEMW-KWQFWETISA-N 0.000 description 1
- HIINQLBHPIQYHN-JTQLQIEISA-N Tyr-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HIINQLBHPIQYHN-JTQLQIEISA-N 0.000 description 1
- ZQOOYCZQENFIMC-STQMWFEESA-N Tyr-His Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)C1=CC=C(O)C=C1 ZQOOYCZQENFIMC-STQMWFEESA-N 0.000 description 1
- QJKMCQRFHJRIPU-XDTLVQLUSA-N Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 QJKMCQRFHJRIPU-XDTLVQLUSA-N 0.000 description 1
- WSFXJLFSJSXGMQ-MGHWNKPDSA-N Tyr-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N WSFXJLFSJSXGMQ-MGHWNKPDSA-N 0.000 description 1
- AUEJLPRZGVVDNU-STQMWFEESA-N Tyr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-STQMWFEESA-N 0.000 description 1
- PRONOHBTMLNXCZ-BZSNNMDCSA-N Tyr-Leu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PRONOHBTMLNXCZ-BZSNNMDCSA-N 0.000 description 1
- KYPMKDGKAYQCHO-RYUDHWBXSA-N Tyr-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 KYPMKDGKAYQCHO-RYUDHWBXSA-N 0.000 description 1
- CGWAPUBOXJWXMS-HOTGVXAUSA-N Tyr-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 CGWAPUBOXJWXMS-HOTGVXAUSA-N 0.000 description 1
- VNYDHJARLHNEGA-RYUDHWBXSA-N Tyr-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 VNYDHJARLHNEGA-RYUDHWBXSA-N 0.000 description 1
- MNWINJDPGBNOED-ULQDDVLXSA-N Tyr-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=C(O)C=C1 MNWINJDPGBNOED-ULQDDVLXSA-N 0.000 description 1
- ZSXJENBJGRHKIG-UWVGGRQHSA-N Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 ZSXJENBJGRHKIG-UWVGGRQHSA-N 0.000 description 1
- MFEVVAXTBZELLL-GGVZMXCHSA-N Tyr-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MFEVVAXTBZELLL-GGVZMXCHSA-N 0.000 description 1
- BMPPMAOOKQJYIP-WMZOPIPTSA-N Tyr-Trp Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C([O-])=O)C1=CC=C(O)C=C1 BMPPMAOOKQJYIP-WMZOPIPTSA-N 0.000 description 1
- JAQGKXUEKGKTKX-HOTGVXAUSA-N Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 JAQGKXUEKGKTKX-HOTGVXAUSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 108010038633 aspartylglutamate Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- VYLVYHXQOHJDJL-UHFFFAOYSA-K cerium trichloride Chemical compound Cl[Ce](Cl)Cl VYLVYHXQOHJDJL-UHFFFAOYSA-K 0.000 description 1
- SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 108010086416 cyclo(arginyl-glycyl-aspartyl-phenylalanyl-cysteinyl) Proteins 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000021061 dietary behavior Nutrition 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- WHRIKZCFRVTHJH-UHFFFAOYSA-N ethylhydrazine Chemical compound CCNN WHRIKZCFRVTHJH-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000002474 gonadorelin antagonist Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 108010092114 histidylphenylalanine Proteins 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 229940041682 inhalant solution Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000007728 intracellular signaling mechanism Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 108010053037 kyotorphin Proteins 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 108010074082 phenylalanyl-alanyl-lysine Proteins 0.000 description 1
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 1
- 108010018625 phenylalanylarginine Proteins 0.000 description 1
- 108010073101 phenylalanylleucine Proteins 0.000 description 1
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 108010083476 phenylalanyltryptophan Proteins 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- 108010084932 tryptophyl-proline Proteins 0.000 description 1
- 108010045269 tryptophyltryptophan Proteins 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 108010017949 tyrosyl-glycyl-glycine Proteins 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 108010078580 tyrosylleucine Proteins 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
Description
517063
A7 B7 五、發明説明(1 ) 本發明係關於式I之生物素化合物
I R1 Q〆 其中 Q 係不存在的,-NH_(CH2)n-CO·或-NH-(CH2)n-NH·, R 1 係 x-Arg-Gly-Asp:Y,A-Cys(R2)-B-U 或環-(Arg-Gly-
Asp-Z),其中Z係與Q之支鏈形成键結,或若q不存 在時便與生物素形成鍵結, X與Y係彼此獨立的’胺基酸殘基或二-,三-,四·或五月太 殘基,其中該胺基酸係彼此獨立地選自包括下列之 Ala,Asn,Asp,Arg,Cys,Gin,Glu,Gly, 4_Hal-Phe,His,同-Phe,lie,Leu,Lys,Met ,Nle,Phe,Phg,Pro,Ser,Thr,Trp,Tyr ,或Val者, 而該胺基酸亦可爲衍生物者, A 係不存在的,A s p或選自包括下列之肽片段,Ala-Asp,Thr-Ala-Asp,Lys-Thr-Ala-As p 9 Lys-Thr-Ala-Asn,Lys-Thr-Gly-Asp ? Lys_Ala_Ala_Asp,Arg-Thr-Ala-Asp, Ser-Ala-Asp, Gln-Ser-Ala-Asp, Glp-Ser-Ala-Asp, Gly-Lys-Thr-Ala-Asp, Asn-Gly-Lys-Thr- _ <4 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁) > 經濟部中央標準局員工消費合作社印製 經濟部中央標準局員工消費合作社印製 517063 A7 B7 五、發明説明(2 )
Ala-Asp,Ile-Ser-Ala-Gly,Arg-Ser-Ala_Gly,Cys_ Asn-Gly-Lys_Thr-Ala-Asp,Tyr-Cys-Asn-Gly-Lys-Thr-Ala-Asp, Asp-Tyr-Cys_Asn_Gly-Lys-Thr_Ala-Asp, Asp_Asp-Tyr_Cys-Asn-Gly-Lys-Thr_Ala_Asp,Gly-Lys-Thr-Cys(Trt)-Asp, Met-Asp-Asp-Tyr-Cys-Asn-Gly-Lys-Thr-Ala-Asp 9 Asp-Met-Asp-Asp-Tyr-Cys-Asn-Gly-Lys-Thr-Ala-Asp, B 係不 存在的 OH, Ala, Arg, A s n ^ Asp, C y s, Gin ,G1 u, G 1 y, His, ,lie, Leu, L y s, Met, 0 r η ,P h e, 4-Hal _Ph e, Pro ,S e r, Thr, Trp, T y r,V a 1或該類胺基酸殘基之N -甲基化衍生物,或 選自包括下列之肽片段Pro-Arg,Pro-Arg-Asn,Pro-Arg-Asn-Pro, Pro-Arg·Asn-Pro-His, Pro-Arg-Asn-
Pro-His-Lys 9 Pro-Arg-Asn-Pro-His-Lys-Gly ^ Pro-Arg-Asn-Pro-His-Ly s-Gly-Pro, Pro-Arg-Asn-Pro-His-Lys-
Gly-Pro-Ala, Pro-Arg-Asn-Pro-His-Lys-Gly-Pro-Ala-
Thr ^ 其中,若R1爲A-Cys(R2)-B-U時,則A或B兩丁基中只有一 個可爲不存在者, R 2 係Η,具1 - 6個碳原子之烷基,T r t,D p m或B z 1, U 係 OH,OR9,NH2,NHR9 或 N(R9)2, Z 在每一情形中係彼此獨立的胺基酸殘基或二-,三-或 四肽殘基,其中其胺基酸亦可以係彼此獨立地選自下 列之 Ala,Asn,Asp,Arg,Cys,Gin,Glu, -5- 本紙張尺度適用中國國家標準(CNS ) A4規格(21〇X297公釐) (請先閱讀背面之注意事項再填寫本頁) y
T 517063 P h e,Pro Μ R3 R4 R5 R6 R7 R8 R9 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明(3 ) G1 y,H i s,11 e,L e ιχ,L y s,M e t Ser,Thi*,Trp,Tyr,Val 或 M 者, 其中該胺基酸亦可爲衍生物者, 而該胺基酸殘基亦可在經常存在Μ之情形下經由“ 胺基與α -羧基形成肽方式之連結, 係nh(r8)-ch(r3)-cooh, 係-R5-R4,-R6-R4,-R7_R4, 係 OH,NH2,SH 或 COOH, 係具1 - 6個碳原子之伸燒基, 係具7-14個碳原子之伸燒基苯基, 係具8-14個碳原子之伸燒基苯伸燒基, 係Η,具1-6個碳原子之烷基或具7_12個碳原子之伸 烷基苯基, 係具1 -6個碳原子之燒基, H a 1 係 F,C 1,B r 或 I 而 η 係 1,2,3,4,5,6,7,8,9 或 1 0 , 其中’若具光活性之胺基酸及胺基酸衍生物之基存在時便 均包括D與L型兩種及其鹽類。 類似的生物素化肽之化合物的説明請參照例如 1\^0 9415956(生物素化内皮體(^11(1〇化61丨11)受體拮抗物), WO 94133 13 (生物素化LHRH拮抗物)或WO 94 18325 (生物 素化壞死因子)。 T. J· Lobl 等人在 Anal· Biochem· 170, 502(1988)中説明在 樹脂之固相合成時將肽生物素化以供改善純化之可能爲目 -6- 表紙張尺度適用中國國家標準(CNS )八4規格(21〇Χ297公釐 (請先閲讀背面之注意事項再填寫本頁)
517063 A7 B7 五、發明説明(4 ) 的。類似之環狀與直鏈肽化合物在DE 43 10 643,DE 43 36 75 8,EP 0 406 428 與 WO 89/05150 中亦已揭示。 本發明之目標係欲發現有價値的新穎化合物,尤其是彼 可供生產藥物之用者。 吾人發現式I化合物及其鹽類因體内容認性良好具極高價 値之藥理性質。特別是,其可做整合素抑制劑,而且其抑 制a v ’ Θ 3或A 5整合素受體與配位體之作用,其例諸如 血纖維蛋白原與3整合素受體之結合。該類化合物在整 合素以/3’ aIIb/?3與及之情形 特別表現其活性。其效應藉由例如J. w. Smith等人,於j Biol. Chem·巧互,12267-12271(1990)中所述之方法便可偵 測知。 血管生成之開始對血管整合素與胞外基質蛋自質間交互 作用之依賴性的説明請參照P· C· Brooks,R. A· Clark與D. A. Cheresh Science 264, 569-71(1994) 〇 藉環狀肽以抑制此交互作用並因而起始血管生成的血管 細胞之胞死(a ρ 〇 p t 〇 s i s )(固定程序之細胞死亡現象的可 經濟部中央標準局員工消費合作社印製 1LW. I - ΙΛΙ n I— n m ........ —I I (請先閱讀背面之注意事項再填寫本頁) 能性之説明請參照 P. C· Brooks, A. M. Montgomery, M. Rosenfeld,R. A· Reisfeld,T. -Hu,G· Klier 與 D. A. Cheresh. €6112^,^57-64(1994)° 可阻斷整合素受體與配位體,其例諸如血纖維蛋白原對 血纖維蛋白原受體(醣蛋白Ilb/IIIa)之交互作用的式I化合 物可如GPIIb/IIIa拮抗物般防止腫瘤細胞經由轉移而散佈, 此可透過下列觀察得到證明: -7- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 經濟部中央標準局員工消費合作社印製 517063 A7 B7 五、發明説明(5 ) 腫瘤細胞由局部的腫瘤散佈至血管系統係經由腫瘤細胞與 血液血小板交互作用形成微凝集物(微血检)后才發生。該 腫瘤細胞因該微凝集物而受屏障保護故不致經免疫細胞辨 識出。 該微凝集物可能全附著於血管壁,此再進一步促使腫瘤 細胞穿透入組織中。由於微血栓係經血纖維蛋白原結合活 化的血小板上之血纖維蛋白原受體之媒介而形成,故吾人 可認爲GPIIa/IIIb拮抗物係對轉移之有效的抑制劑。 我們可將式I化合物做爲人體醫學及獸醫學中之醫藥物質 之用,特別是預防與或治療血栓,心肌梗塞,動脈硬化, 發炎,中風,狹心症,腫瘤病,諸如骨質疏鬆症之骨質溶 解症,病理性血管生成障礙,其例諸如發炎,眼科疾病, 糖尿病引起之視網膜病變,斑點變性,近視,眼睛組織漿 菌病,類風濕性關節炎,骨關節炎,發紅性青光眼,潰瘍 性結腸炎,克隆氏病,動脈硬化,牛皮癬,血管造形術后 之再狹窄,病毒感染,細菌感染,眞菌感染,急性腎衰竭 及治療傷口時支持治療流程之用。 式I的化合物亦可在插入生物性物質,植入物,導管或心 律調整器之手術時做爲有效的抗菌物質之用。在此情形下 ,其便是做抗菌劑之用。其抗菌活性之效果可使用P Valentin-Weigund 等人在 Infection and Immunity,2851-2855 (1988)中所述方法表示。 因式I化合物係血纖維蛋白原結合之抑制劑因而係血小板 上血纖維蛋白原受體之配位體,故其可做體内血管系統血 -8- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁) 、τ 517063 A7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明(6 ) 栓偵測與定位之診斷幫助物,因爲該生物素基係U V可偵 測的基。 式I化合物可做血纖維蛋白原結合之抑制劑,亦可做研究 血小板不用階段的活化之新陳代謝或血纖維蛋白原之胞内 傳訊機制之有效幫助物之用。”生物素標示”后之可偵測單 元使吾人可在其與受體結合后調查該機制。 此處前后所使用的胺基酸殘基之縮寫表示下列胺基酸的 基··
Abu 4 -胺基丁酸 Aha 6-胺基己酸 Ala 丙胺酸 A s η 天冬_胺 Asp 天冬胺酸 Arg 糟胺酸 C y s 半胱胺酸 Dab 2,4 -二胺基丁酸 Dap 2,3 -二胺基丙酸 Gin 麩胺醯胺 Glp 麩醯胺酸 Glu 麩胺酸 G 1 y 甘胺酸 His 組胺酸 homo-Phe 同-苯丙胺酸 lie 異白胺酸 -9 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁) 一裝 l·訂l· 517063 A7 B7 五、發明説明(7 經濟部中央標準局員工消費合作社印製
Leu 白胺酸 L y s 離胺酸 Meth 甲硫胺酸 Nle 正白胺酸 0 r η 鳥胺酸 P h e 苯丙胺酸 Phg 苯甘胺酸 4-Hal-Phe 4 -函素-冬丙胺 Pro 脯胺酸 S e r 絲胺酸‘ Thr 蘇胺酸 T r p 色胺酸 T y r 酪胺酸 Val 纈胺酸 and Bit ϊ Η 广JUn S VT'N i Η Η
進一步意義者,係如下列: BOC 第三-丁氧羰基 CBZ 芊氧羰基 (請先閱讀背面之注意事項再填寫本頁) 10- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 517063 A7 B7 五、發明説明(8 經濟部中央標隼局員工消費合作社印製 DCCI 一 %己幾二亞酿胺 DMF 二甲基甲醯胺 Et 乙基 Fmoc 9 -苐基甲氧羰基 HOBt 1 -羥基苯并三唑 Me 甲基 MBHA 4 -甲基二苯甲胺 Mtr 4 -曱氧基-2,3,6 -三甲基苯基碍醯基 OBut 第三-丁酯 OMe 甲基酯 OEt 乙基酉旨 POA 苯氧乙酿基 TFA 三氟乙酸 Trt 三苯甲基 若上述胺基酸有數種對映體型式則全部這些型式及直混 合物(例如D L型式)亦皆爲此處前后所包括,例如式j化合 物之組成份者 。甚且,該胺基酸亦可採用本身已知之適當 保護型式供給 ,例如式I化合物之組成份者。 根據本發明之化合物亦包括所謂藥物前體衍生物,亦即 ’已經過修飾之式I化合物,例如以烷基或醯基,糖或寡 肽修飾其在體内會迅速分解成根據本發明之活性化人物。 本發明甚且有關製備根據申請專利範圍第i項之式ι化合 物及其鹽類之方法,其特徵爲 (a)式II化合物 -11 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁)
517063 A7 B7 五、發明説明(9 H-Q-R]
II 其中 .久、· Q與R1具根據申請專利範圍第1項所述思義者’其在一醯化 反應中與式III化合物反應 ·'
(請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 其中 L係C 1,B r,I或係游離的或係經反應性功能修飾之 OH基, 或是 b)[本文如此]其具式IV化合物 H-Ri IV 其中 R 1具根據申請專利範圍第1項所述意義者,其在一醯化反 應中與式V化合物反應
-12 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 517063 A7 __B7 ___ 五、發明説明(10 ) 其中 Q 具根據申請專利範圍第1項所述之意義,而 L 係H,C 1,B r,I或係游離的或係經反應性功能修飾 之OH基, 或是 c)其係經由溶液解離劑或氫解劑處理而由其功能性衍生物 釋出者’與/或其係式I之驗性或酸性化合物且係經由酸 或驗處理的成爲其鹽類者。
本文中除非另有説明,否則Q,r 1與L基便異所述式I,II 與III之意義。 上述諸式中烷基以甲基,乙基,異丙基或第三-丁基較 佳。 伸烷基以亞甲基,乙烯,丙烯,丁烯,戊烯或己晞。伸 fe基苯基以苯甲基或苯乙基較佳。伸燒基苯基伸燒基以4 -亞甲基卞基或4 -乙缔爷基者較佳。 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) •R6-R4基以2-,3 -或4-¾苄基,2-,3·或4_胺;基, 2·,3 -或4-統苄基,2-,3 -,4_叛苄基較佳;甚且_,3-或4 -羥苯乙基,2 ·,3 -或4 -胺苯乙基,2 _,3 _或4 -銃苯 乙基或是2 -,3 -或4 -羧苯乙基益佳。 Q係以6 -胺基己酸(6 -胺基己酸)或不存在爲佳。 Μ係以 Dap,Ser,Cy s,Asp,D-Asp,Dab,同絲胺 酸,同半胱胺酸,Glu,D-Glu,Thr,〇rn,Lys,D-Lys,4-胺基甲基-Phe或4-胺基甲基-D-Phe爲佳。 X係以 Ala, Asn, Asp, Arg, Cys, Gin, Glu, -13- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐Ϊ~" " ~----- 517063 經濟部中央標準局員工消費合作社印製 A7 B7五、發明説明(11 ) Gly,His,lie,Leu ^ Lys,Met,Phe,Pro,Ser, Thr,Trp,Tyr 或 Val爲佳,甚且以 Lys_Gly,Lys-Ala, Lys-y5 -Ala ’ Tyr-Gly, Tyr-Ala, Tyr-y5 -Ala, Phe-Gly, Phe-Ala 9 Phe-/? -Ala 9 Tyr-Gly-Gly 9 Phe-Gly-Gly 9 Lys-Gly,Gly,Tyr-Gly-Ala,Phe-Gly-Ala,Lys-Gly-Ala,Arg-Gly_Asp,Lys-Gly-Gly-Gly,Tyr-Gly-Gly-Gly,Phe-Gly-Gly-Gly,Lys-Gly-Gly-Ala,Tyr-Gly-Gly-Ala,Phe-Gly_ Gly-Ala, Lys-Gly-Gly-y5 -Ala, Tyr_Gly-Gly_yS -Ala, Phe-Gly-Gly-β -Ala, furthermore also Lys-Gly-Gly-Gly-Gly,Tyr-Gly-Gly-Gly-Gly,Phe_Gly-Gly_Gly-Gly,Lys_ Gly-Gly-Ala-Gly,Tyr-Gly-Gly-Ala-Gly,Phe-Gly-Gly-Ala· Gly,Lys-Gly-Gly-y3 -Ala-Gly,Tyr-Gly-Gly_y5 -Ala-Gly, 或 Phe-Gly-Gly->5 -Ala-Gly 更佳。 Y係以 Ala, Asn, Asp, Arg, Cys, Gin, Glu, Gly,His,lie,Leu,Lys,Met,Phe,Pro,Ser, Thr,Trp,Tyr 或 Val爲佳,甚且以 Tyr-Ala,Tyr-Asn, Tyr_Asp,Tyr_Arg,Tyr-Cys,Tyr-Gln,Tyr-Glu,Tyr-Gly,Tyr-His,Tyr-Ile,Tyr-Leu,Tyr-Lys,Tyr-Met, Tyr-Phe,Tyr-Pro,Tyr-Ser, (請先閲讀背面之注意事- I# 項再填、 裝II 寫本頁) 、?τ -14- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 517063 A7 B7五、發明説明(12 ) 經濟部中央標準局員工消費合作社印製
Tyr-Thr, Tyr-Trp, Tyr-Tyr,Tyr-Va!t Phe-Ala, Phe-Asnt Phe-Asp, Phe-Arg, Phe-Cys, Phe-Gtn, Phe-GIut Phe-Giy, Phe-His, Phe-4le( Phe-Leu, Phe-Lys, Phe-Met, Phe-Phe, Phe-Prot Phe-Ser, Phe-Thr, Phe-Trp, Phe-Tyr, Phe-Vai, Trp-Ala, Trp-Asn, Trp-Asp, Trp-Argt Trp-Cys, Trp-Glnf Trp-Glu, Trp-Gfy,丁rp-His, Trp-lle· Trp-Leu, Trp*Lys,Trp*Met T「p-Phe, Trp-Pro, Trp-Ser, Trp-Thr, Trp-Trp, Trp-Tyr, Trp-Val, Asp-Ala, Asp-Asn, Asp-Asp, Asp-Arg, Asp-Cys, Asp-Gin, Asp-Glu, Asp-Gly, Asp-Hist Asp-Ile, Asp-Leu, Asp-Lys, Asp-Met, Asp-Phe, Asp-Pro, Asp-Sert Asp-Thr, Asp-Trp, Asp-Tyr, Asp-Val, Ser-Pro-Lys, Tyr-Pro-Lys, Phe-Pro-Lys, Trp-Pro-Lys, Asp-Pro-Lys, Ser-Gly-Lys, Tyr-Gfy-Lyst Phe-Gfy-Lys, Trp-Gly-Lys, Asp-Gly-Lys, Ser-AIa-Lys, Tyr-Ala-Lys, Phe-Ala-Lys, Trp-Ala-Lys, Asp-Ala-Lys, Ser-Pro-Ala, Ser-Leu-Lys, Tyr-Leu-Lys, Phe-Leu-Lysf Trp-Leu-Lys, Asp-Leu«Lys, Ser-Ile-Lys, Tyr-IIe-Lys, Phe-Ile-Lys, Trp-IIe-Lys, Asp-iie-Lys, Ser-Pra-Ala-Ser, Tyr-Pro-AIa-Ser, Phe-Pro-Ala-Ser, Trp-Pro-AIa-Ser, Asp-Pro-Ala-Ser, Ser-Gly-AIa-Serr Tyr-Giy-Ala-Ser, Phe-Gly-Ala-Ser, Trp-Giy-Ala-Ser, Asp-Gly-Aia-Ser, Ser-Ala-Ala-Ser, Tyr-AIa-AJa-Ser, Phe-AIa-AJa-Ser, Trp-Ala-AJa-Ser, Asp-Ala-Ala-Ser, Ser-Val-Ala-Ser, Tyr-Val-Ala-Ser, Phe-Val-Ala-Ser, Trp-Val-Ala-Serf Asp-Val-Ala-Sert Ser-Leu-Ala-Ser, Tyr-Leu-Ala-Ser, Phe-Leu-Ala-Ser, Trp-Leu-Ala-Ser, Asp-Leu-Ala-Ser, Ser-lle-Ala-Ser, Tyr-lle-AJa-Ser,Phe*lle-AIa_Ser,Tn>lle-Ala-Ser, Asp~Ue«Aia^Ser,更佳,甚 jl 亦可以是Ser-Pro»Ala-Ser-Ser,Tyr-Pro-Ala-Ser-Ser, Phe^Pro^AJa-Ser-Ser, Trf>PrchAla-Ser_Ser, Asp-ProAla-Ser-Ser, SeM3fy-Ala~Se卜Ser, Tyr-Gly-Ala^Ser-Ser, Phe-Gly-Aia-Ser-Ser, Trp-Gfy-AJa-Ser-Ser, Asp-Gty-AJa-Ser-Ser, Ser-Ala-Aia-Ser-Ser, Tyr-Ala-AJa-Ser-Ser, Phe-Ala-Ala-Ser-Ser, Trp-Ala-Ala-Ser-Ser, Asp-AIa-Aia-Ser-Ser, Ser-Val-Ala-Ser-Ser, Tyr-Val-Ala-Ser-Ser, Phe-Val-AJa-Ser-Ser, TrpA/al-Ala-Ser-Ser, AspA/al-Ala-Ser-Ser, Ser-Leu~Ala-Ser-Ser, Tyr-Leu-Ala-Ser-Ser, Phe-Leu-Aia-Ser-Ser, Trp-Leu-Ala-Ser-Ser, Asp-Leir-Ala-Ser-Ser, Ser-lle-Aia-Ser-Ser, Tyr-lie-Ala-Ser-Ser, Phe-lle-Ala-Ser-Ser, TrHIe-AJa-Ser-Ser 或 Asp-ne^\la-Ser-Ser· -15- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) l·——· ·1 ^ι_ϋ m ml - - - ϋϋ 士ϋϋ Λ 義 (請先閱讀背面之注意事項再填寫本頁) --*-1 1ίι - - -y- —1 、? 5l7〇63 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明(13) 在X,Y與Z的意義下所提到的胺基酸及胺基酸殘基亦可 爲衍生性者,又以N -甲基,N -乙基,N -丙基,N-苄基或 C α _甲基之衍生物較佳。 此外A s ρ與G1 u之衍生物亦佳,特別是支鏈羧基之甲基 乙基’丙基’ 丁基’第二-丁基’新戊基或爷基g旨,甚 且亦包括在其-nh-c(=nh)-nh2s上可經乙醯基,苯甲醯 基,甲氧羰基或乙氧羰基取之A r g的衍生物。 甚且,在X,Y與Z意義下所提到的胺基酸及胺基酸殘基 亦可以其本身已知含適當保護基之型式供應。 Z以Μ較佳,甚且較佳者係爲〇_卩1^-1^,0_1^?_1^,0-Tyr-M,D-Phe-Lys,D-Phe-D-Lys,D-Trp-Lys,D-Trp-D-Lys,D-Tyr-Lys,D-Tyr-D-Lys,D-Phe-Orn,D-Phe-Dab ,D_Phe-Dap,D-Phe_D-Orn, D-Phe-D-Dab,D_Phe_D-Dap,D-Phe-4-胺甲基-Phe,D-Phe-4-胺甲基 _D_Phe,D-Trp-4-胺甲基-Phe,D-Trp-4-胺甲基 _D-Phe,D-Tyr-4-胺甲基-Phe,D_Tyr-4-胺甲基-D-Phe,D-Phe-Asp,D-Phe_D-Asp,D-Trp-Asp,D-Trp-D-Asp,D_Tyr-Asp,D-Tyr-D-Asp,D-Phe-Cys,D-Phe-D_Cys,D-Trp-Cys,D-Trp-D-Cys,D_Tyr-Cys,D-Tyr-D-Cys,Phe-D-Lys,Trp-D_Lys,Try_D-Lys,Phe-Orn,Phe-Dab,Phe_Dap,Trp-Orn,Trp-Dab,Trp-Dap,Tyr-Orn,Tyr_Dab,Tyr-Dap, P h e - 4 -胺甲基-D-Phe,Trp-4-胺甲基-D-Phe,Tyr-4-胺甲 基-D-Phe,Phe-D_Asp,Trp-D-Asp,Tyr-D-Asp,Phe-D-Cys,Trp-D-Cys,Tyr-D-Cys,D-Phe-Lys-Gly,D-Phe-M- -16- 氏張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) an-— κι —^ϋ m - - ϋϋ ϋϋ ϋ 秦 4 (請先閲讀背面之注意事項再填寫本頁) 訂 517063 A7 B7 五、發明説明(14 )
Gly,D-Trp-Lys_Gly,D_Trp_M-Gly,D-Tyr-Lys-Gly,D_ Tyr-M-Gly,D-Phe-Val-Lys,D-Phe-Gly-Lys,D-Phe-Ala-Lys,D-Phe-Ile_Lys,D-Phe-Leu-Lys,D-Trp-Val-Lys,D-Trp-Gly-Lys ^ D-Trp-Ala-Lys ^ D-Trp-Ile-Lys ^ D-Trp-Leu-Lys,D-Tyr-Val-Lys,D-Tyr-Gly-Lys,D-Tyr-Ala-Lys,D_ Tyr-Ile-Lys,D-Tyr-Leu-Lys,甚且亦可爲 M-Pro-Ala-Ser-Ser 〇 式I化合物可能具1個或1個以上之掌型中心因而存在不 同立體異構物型式。式I包括所有這些型式。 據此,本發明係特別關於彼具式I之化合物其中至少該基 之一具如上所示較佳性質之意義者。某些較佳類之化合物 可用下列相當於式I之部份式la至If表示而且其中玆未定 義之基具所述式I之意義,但其中 (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 在la中 Q 係不存在而 R1 係 X-Arg-Gly-Asp- Y ; 在I b中 Q 係-NH-(CH2)5-CO-而 R1 係 X_Arg-Gly_Asp-Y ; 在I c中 Q 係-NH-(CH2)5-CO-而 R1 係環-(Arg-Gly-Asp-Z) 在I d中 Q 係-NH-(CH2)5-CO-而 R1 係環-(Arg-Gly-Asp-M) 在I e中 Q 係-NH_(CH2)5-CO-而 而且 R1 係 A-Cys(R2)-B ; -17- 本紙張尺度適用中國國家標準(CNS ) A4規格(21〇χ297公釐) 經濟部中央標準局員工消費合作社印製 517063 A7 _____B7 五、發明説明(15 ) 在1f 中 Q 係-NH-(CH2)n-CO-, R1 係 X-Arg-Gly-Asp_Y 而 n 係 1,2,3,4,5 或 6。 式I化合物及其製備所需之起始物質甚且係以本身已爲人 熟知之方法製成其説明可參照文獻(例如標準程式暑 Houben-Weyl, Methoden der organischen Chemie [Methods of organic chemistry],Georg_Thieme-Verlag,Stuttgart),其特別 在吾人熟知適於該反應之反應條件下進行。甚且亦可能利 用其本身已知但在本文未詳細提及之變體。 起始物質在必要時亦可在原位上形成因此可不須自反應 混合物分離出而可立即進一步轉化式I化合物。 式I化合物以藉由式11化合物與式III化合物之反應可較 易獲得。 通常式II及式III化合物係已知的。若係未知者吾人可 採用已知之方法製備之。 在式III化合物中之-CO-L基係一易反應之幾酸,以齒化 黢對稱或混合酸酐或活性醋較佳。此種型態之在典型驢化 反應中活化羧基的基可在文獻中見其説明(例如,在標準 程式中之諸如 Houben-Weyl, Methoden der organischen Chemie,
Georg-Thieme-Verlag,Stuttgart)。活化酯以原位形成者較佳 ,例如可藉添加HOBt或N,經基琥珀亞醯胺l以Hc i, B r或-〇 N 琥珀亞醯胺較佳。 該反應通常係在惰性溶劑中含酸結合劑,以有機驗較佳 ,諸如三乙胺,二甲基苯胺,吡啶或喹啉或過量式ΠΙ之幾 __ _ 18- ^紙張尺度適用中國國家標準(CNS ) Α4規格(210X 297公釐) ' ------- C請先閱讀背面之注意事項存填寫本頁〕
經濟部中央標準局員工消費合作社印製 517063 A7 —-----_B7 五、發明説明(16 ' ' —" ----- ^:m下進行。添加鹼金屬或鹼土金屬氫氧化物,碳 2雀,故氫鹽或驗金屬或驗土金屬的弱酸之其他鹽類, 欠丰^鈣或铯者較佳亦可有所幫助。反應時間視所用 。而疋。’其介於數分鐘至丨4天之間,反應溫度介於約 140 ’正常是·1〇。〜90。特別是約〇。〜約70。。 :h ϋ各劑之實例爲煙類,諸如己燒,石油醚,苯 苯或一甲表,氯化煙諸如三氯乙晞,1,2 -二氯乙燒 四氫甲垅,氣化或二氯甲烷,醇類,諸如甲醇,乙醇, :丙醇,正_丙醇,正丁醇或第三丁醇,醚類,諸如乙 酸’異丙,四氫呋喃(THF)或二呤烷,二醇醚類,諸如 乙、烯二醇一甲基或一乙基醚(甲基二醇或乙基二醇),乙烯 二醉二甲_ (雙(2 -甲氧乙)醚,酮類,諸如丙酮或丁酮, 驗胺諸如乙醯胺,二甲基乙醯胺或二甲基甲醯胺(DMF), 月膏類諸如乙腈,砜類,諸如二甲砜(DMSO),二硫化碳, 叛酸諸如甲酸或乙酸,硝基化合物,諸如硝基甲烷或硝基 表’醋類’諸如乙酸乙酉旨,水或所提及溶劑之混合物。 式I化合物甚且可藉式IV化合物與式V化合物進行反應而 獲得。式IV及式V之起始化合物通常係已知的。若彼係未 知的,便可採本身已爲人熟知的方法行其製備。 式V化合物中之_C〇_L基係一經預活化羧酸,以鹵化羰 基’對稱的或混合的酸酐或活性酯較佳。此種型態之在典 型醯化反應中活化羧基的文獻中有所説明(例如在標準程 式者諸如 Houben-Weyl,Methoden der organischen Chemie, Georg-Thieme-Verlag,Stuttgart),L以 Cl,Br 或-ON-琥珀 -19- 本紙張尺度適用中國國家標準(CNS ) A4規格(21 OX297公釐) (請先閱讀背面之注意事項再填寫本頁) I裝_ -訂 517063 五、發明説明(17 ) 亞酿胺較佳。 式IV與式V化合物之反應條件與式π和式ΙΠ化合物進行 反應時所用有關之反應時間,溫度與溶劑相同。 彼 R1係 X-Arg-Gly-Asp-Y 或 A_Cys(R2)-B 之式 I 的直線開 放鏈化合物可在固相合成之最后步驟以生物素在一同循環 週期中做正常的N -終端保護胺基酸做最后成份,並於正常 條件下自樹脂上切除生物素-肽而進一步取得。該固相合 成,切除與純化之進行皆如Α· Jonczy]^ j· Meienh0fei^
Peptides,Proc· 8th Am. Pept· Symp·, Eds. V. Hruby 與 D H
Rich,Pierce Comp· ΙΠ 73_77 頁(1983)所述或與 Angew Chem,1M,375-391(1992)中所述技術類似。 式II與式V之開放鏈直線化合物甚且可如所述藉傳統胺 基酸及肽合成法加以製備,例如在標準程式及所提及之專 利申請中,例如亦可參照Merrifield之固相合成(B. F. Gysin 與 R· Β· Merrifield,J. Am. Chem. Soc. 94? 3 102 ff.(1972)) 〇 其中R1爲環狀-(Arg-Gly-Asp-Z)之式II與式I v之環狀化 合物亦可如所述經環化直線化合物而製成,例如De 43 1〇 643 或 Houben-Weyl,1. c·,15/11 册 1 〜806 頁(1974)。 式[原文如此]I化合物亦可進一步藉由溶劑解離特別是水 解或氫解將其自官能基衍生物上釋放出來而取得。 溶劑解離或氫解之較佳起始物質係彼原位在對應經保護 的胺基與/或羥基,包括一或多個游離的胺基與/或輕基者 ’較佳者係彼在Η原子位置上連接於胺保護基之ν原子, 例如彼對應於式I但原位包括一 ΝΗ2基與NHR’基者(其中Rf -20- 本紙張尺度適用中關家標準(CNS ) M規格(21Qx297公釐 (請先閱讀背面之注意事項再填寫本頁)
經濟部中央標準局員工消費合作社印製 517063 A7 I-------------- -- B7 _ I五、發明說明(18 ) 係一種胺基保護基,例如B〇C或CBZ)。 更佳之起始物質係彼在Η原子原位上爲羥基之羥保護基 ^,例如彼相當於式^旦本身在羥苯基位置則係包括R,,〇_ 苯基者(其中R ”係羥基保護基)。 起始物質中亦可能含有數個相同或不同之保護性胺基 與/或羥基。若所含之保護基彼此不同,在很多情形下常 可加以選擇性地切除。 胺基保護基”之用語係吾人通常熟知者且意指彼適於保 護(阻斷)胺基免於化學反應,但在其分子之他處所進行之 必要的化學反應完成后可很容易地除去之基而言,典型的 此種型態之基係特別地指未經取代或經取代之醯基,芳基 ,芳烷氧甲基或芳烷基。因必要反應(或系列反應)后胺基 保護基便會除去,其性質與分子大小並不頂重要,然而彼 具1〜20特別是1·8個碳原子者爲佳。,,醯基”之用語在本發 明方法下係採最廣義解釋。其包括衍生自脂肪族的,芳脂 肪'族的’芳香族的或雜環的叛酸或橫酸的酿基,特別是燒 氧羰基,芳氧羰基,尤其是芳烷氧羰基。此類型醯基之實 | 例係娱》SS基諸如乙it基,丙醯基、丁醯基,芳燒醯基,諸 如苯乙醯基,芳醯基,諸如苯甲酿基或甲苯酿基,芳氧燒 醯基,諸如Ρ Ο A,烷氧羰基,諸如甲氧羰基,乙氧羰基, 2,2,2_三氯乙氧羰基,BOC,2_碘乙氧羰基,芳烷氧羧 基,諸如C B Z ( ”羰苯甲醯氧基”),4 -甲氧苄氧羰基, FMOC,芳續SS基,諸如M t r。較佳之胺基保護基係b 〇 c 與Mtr,亦包括CBZ,Fmoc,字基與乙醯基。 |_ .魯 1紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐)~" '-- (請先閱讀背面之注意事項再填寫本頁)
517063 A7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明(19 ) ’’羥基保護基”之用語同樣係吾人通常所熟知者且意指適 於保護羥基免於化學反應,但在其分子之他處所進行必要 之化學反應完成后可很容易地除去之基而言,典型的此種 型態之基係上述之未經取代或經取代之芳基,芳烷基或酸 基以及虎基。該羥基保護基之性質與大小,因其在必要之 化學反應或系列反應后便會除去,通常特別是個 碳原子之基較佳。羥基保護基之實例包括苄基,對_硝基 冬甲SS基,對-甲燒續g盛基,第三-丁基與乙酿基,又以苄 基與第三丁基特佳。天冬胺酸與麩胺酸之c〇〇H基以其第 三-丁酯(例如Asp(〇 But))型式進行保護較佳。 將式I化合物自其官能衍生物釋出之反應在進行時視所用 保護基而定,例如可用強酸,以TF A或過氯酸較佳,,但亦 可使用其他強典機fe諸如氫氯酸或硫酸,強有機叛酸諸如 三氯乙酸或磺酸諸如苯-或對-甲苯磺酸。亦可存在另一堕 性溶劑,但此非必要,適合的與較佳之堕性溶劑係有機的 例如敗,諸如乙,醚類,諸如四氫吱喃或二氧燒,酸 胺諸如DMF,卣化烴諸如二氯甲烷,亦包括醇類,諸如 甲醇,乙醇或異丙醇以及水。上述溶劑之混合物亦適當。 T F A以過量使用而不加其他溶劑爲佳,過氣酸使用時則係 以乙酸及7 0 %過氣酸9 : 1比例之混合物爲佳。切除時之反 應溫度以界於約[原文如此]與約5〇。,以15〜3〇。(室溫) 爲佳。 BOC,OBut與Mtr基切除時可使用例如TFA之二氯甲烷 溶液或以約3〜5 N HC1之二氧烷溶液,15〜3〇。行之較佳, 各紙張尺度適用中國國家標準(CNS ) A4規 (請先閱讀背面之注意事項再填寫本頁) L--'-訂 -22- 甲胺或p比淀 517063 五、發明説明(2〇 )
Fmoc基則以約5〜50〇/〇二甲胺溶液行之較佳 之DMF溶液15〜30。。 吾人用三苯甲基以保護組胺酸,天冬醯酸,麩胺醯胺盥 半胱胺酸等胺基酸。進行之切除反應視所需終產物而定 以TFA/10%硫酚爲例,此情形下在所有提及的胺基酸上之 三苯甲基皆會被切除,而當使用TFA/苯甲醚或tfa/苯甲 硫醚時,只位於Hls,Asn及Gln上之三苯甲基會被切除 ’而位於C y s支鏈上者仍會存留其上。 可經氫解去除之保護基(例如CBZ或苄基)亦可加以切除 ’例如在存有催化劑條件下以氫處理之(例如貴重金屬催 化劑諸如鈀,又以位於支持物諸如碳上較佳)。此情形下 之適^ ;谷劑係彼如上述者,尤其是例如醇類,諸如甲醇或 乙@予或是驢胺諸如D M F。通常,氫解的條件係在溫度介 於約0〜100。而壓力介於約!至2〇〇巴,以2〇〜3〇。與i〜i 〇 巴幸父佳。c B Z基氫解例如在5〜10% Pd/C甲醇液或甲酸鼓[ 原文如此](取代氫)之Pd/C的甲醇/DMF 20〜30。條件下非 常容易進行。 式I的鹼可經酸轉化成對應的酸加成鹽,例如在諸如乙醇 之惰性溶劑中令等當量之鹼與酸反應並加蒸發。特別適於 此反應之酶係彼可供給生理可接受的鹽者。因此,吾人可 能使用無機酸,例如硫酸,硝酸,氫卣酸,諸如氫氯酸或 氫溴酸,磷酸諸如正磷酸,胺磺酸亦可使用有機酸特別係 脂肪族,脂環族,芳脂族,芳香族或雜環族單元或多元羧 酸,橫酸,或硫酸,例如甲酸,乙酸,丙酸,三甲基乙酸 23 本紙張尺度適用中國國家標準(CNS )八4規格(210X297公釐 f — ί-----^裝—— (請先閱讀背面之注意事項再填寫本貢) trf 經濟部中央標準局員工消費合作社印製 517063 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明(21 ,二乙基乙酸,丙二酸,琥珀酸,庚二酸,反丁烯二酸, 順丁烯二酸,乳酸,酒石酸,蘋果酸,檸檬酸,葡萄庚酸 ,抗壞血酸,菸鹼酸,異菸鹼酸,甲烷或乙烷磺酸,乙烷 二磺酸,2 -羥基乙烷磺酸,苯磺酸,對-甲苯續酸,笔單 一與雙-磺酸,十二基硫酸。不具生理可接受的酸之鹽, 例如苦味酸,可用以分離與/或純化式I的化合物。 另一方面,吾人可令式I的酸與鹼進行反應而生成其生理 可接受的金屬或銨鹽。此種關係下特別適合的鹽係鈉,鉀 ,鎂,鈣與銨鹽,亦含經取代的銨鹽例如二甲基_,二乙 基-或二異丙基銨鹽,單乙醇_,二乙醇_,或二異丙基銨 鹽’環己基’ 一 5尽己基铵鹽’二;基乙晞二銨鹽,甚且是 例如精胺酸或離胺酸的鹽。 本發明甚且關於式I化合物與/或其生理可接受的鹽生產 醫藥製劑’特別是採用非化學方法者之用途。爲此目的, 可私之轉化成適當的劑f型式加上至少一種固體,液體與 /或半固體載體或佐劑而JL適合時更可合併一或多種其他 有效物質使用。 本發明進一步關於醫藥製劑,其包括至少一種式I化合物 與/或一種其生理可接受的鹽。 這些製劑可做爲人或獸醫學上醫物之用。適當的载體係 有機或典機物而適於經腸的(例如口服),非經腸,局部施 用或吸入的噴劑之施用型式而不與該新穎化合物反應者, 例如水,蔬菜油,苄醇,烷二醇,聚乙二醇,三乙酸甘油 醋,明膠,醣類,諸如乳糖或澱粉,硬脂酸鎂,滑石,石 (請先閲讀背面之注意事項再填寫本頁)
-24 - 517063 五、發明説明(22 ) 臘脂。口服者特別是爲錠劑,藥丸,塗覆錠劑,膠囊,於 粒,糖漿,溶液或滴劑,非經腸施用者係溶液,二 或水性歧較佳,甚且㈣浮液,乳化液或植入劑, 局部施用者係油膏,乳霜或粉末。該新顆化合物亦可以θ ^東乾燥者而可使用該生成之冷滚乾燥物例如製成注射: 物。所示之製劑可經滅菌與/或包括佐劑,諸如潤滑劑, 防腐劑,安定劑與/或遂潤劑,乳化劑,影響渗透壓的鹽 ,μ物’色素’增味劑與/或其他數種有效物質,例如 -或多種維生素。可做吸入噴劑之用的噴劑包括溶解或懸 序於推進氣體或推進氣體混合物之有效物質該氣體(例如 匸〇2或氟氯化碳)。此情形下,所用的有效物質最好是微粒 化者,亦可能添加一或多種生理可忍受的溶劑例如乙醇。 施用吸入溶液亦可使用傳統的吸入器。 式I化合物及其生理可接受的鹽可做整合素抑制劑之用以 控制疾病,特別是病理性血管生成障礙,血栓,心肌梗塞 ,冠狀動脈心臟病,動脈硬化,腫瘤,骨質疏鬆症,發炎 與感染。 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 爲此目的,通常吾人可採用類似其他已知市售之肽的方 法施用根據本發明之物質,特別是以類似us_a-4 472 305 所述化合物之施用法者,其劑量以介於約〇 〇 5及5 〇 〇毫克/ 劑量單位,特別是介於0.05及100毫克/劑量單位。每天劑 量以介於約0.01及2毫克/公斤體重較佳。然而,每一病人 之比劑量(specific dose)視多種因素而定,例如所使用之特 定化合物的活性患者,年齡,體重,一般健康狀況,性別 -25 本紙張尺度適用中國國家標準(CNS ) M規格(21〇><297公釐 經濟部中央標準局員工消費合作社印製 517063 A7 B7 五、發明説明(23 ) ,膳食行爲,施用時間與途徑,排泄速率,藥物組合與欲 治療的特定病症之嚴重性而定。非經腸的施用方式較佳。 式I之新穎化合物可進一步供分析生物學與分子生物學之 用。此只限於利用生物素基會與糖蛋白,抗生物素蛋白形 成錯合物之能力的部份。生物素-抗生物素抗白錯合物之 用途請見 E. A. Bayer 與 M· Wilchek 在 Methods of Biochemical Analysis 攻 l-45(1980)(Lit. 1)之揭示。 式I之新穎化合物可做整合素配位體之用以生產供製備純 的整合素之親和力色析管柱。抗生物素蛋白衍生之支持物 質的錯合物,例如瓊脂糖(Sepharose)及式I之新穎化合物 係採用本身已知的方法製成例如在Lit. 1中所述者。 爲此目的,在此點上吾人並未對此法進一步細述,至於 參考文獻則引自相關文獻,例如Lit· 1。 適合的聚合物支持物質係彼在肽化學中已知之聚合的固 相層並以具親水性質者爲佳,例如交聯多St諸如纖維素, 瓊脂糖或SephadesR,丙晞醯胺,以聚乙二醇之聚合物或似 觸手聚合物R。 該新穎之式I化合物亦可供ELISA-型分析及FACS (螢光 活化之細胞分類器)分析中之抗-生物素抗體反應之診斷標 識體之用。M. Berger, Biochemistry L4, 2338-2342 (1975) 揭示了以抗生物素抗體偵測生物素之用途。至於在酵素免 疫分析(ELIS A)中免疫球蛋白IgG衍生以生物素者之用途 的説明請見 U. Holmkov-Nielsen 等人 Journal of Chromatography, 297, 225-233 (1984)。 -26- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) (請先閲讀背面之注意事項再填寫本頁) 訂 517063 A7 B7 五、發明説明(24 ) J· Gao 與 S. J· Shattil 在 J· Immunol· Methods 181,55-64 (1995) 中説明一種可偵測會抑制整合素^ lib A III活化的物質之 ELISA試驗。此情形下,吾人使用生物素化之血纖維蛋白 原行偵測。 流動細胞計數法在臨床上細胞診斷之用法之説明請見G· Schmitz 與 G. Rothe,DG Klinische Chemie Mitteilungen 24 (1993) No· 1,1〜14 頁。 式I化合物可進一步用於力場顯微鏡(原子力顯微鏡法 A F Μ )以測定配位子·受體交互作用之強度。配位體較佳者 意指抗生物素抗白與新穎的式I化合物之錯合物。受體較 佳者意指整合素受體。E. -L· Florin等人。在Science 264, 415-417(1994)中説明抗生物素蛋白功能化力場顯微鏡與生 物素化瓊脂糖間吸附力的測定方法。 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 此外前后文所用之溫度皆爲°C。在下列實例中”通常調 整步驟”(usual working up)意指:必要時會添加水,必要 時,視終產物之組成,調p Η至2〜10之間,萃取時以乙酸 乙酯或二氯甲烷行之,分離有機層,經硫酸鈉脱水並蒸發 ,純化係經矽膠色析與/或結晶行之。矽膠上之R f值,移動 相:乙酸乙酯/甲醇9 : 1。 R T =在下列系統之HPLC中的滯留時間(分鐘): [A] 管柱: Nucleosil 7C18 250 X 4 毫米 溶離溶A : 0.1%TFA水溶液 溶離液B : 0.1% TFA乙腈溶液 -27- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 517063 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明(25 ) 流速: 1毫升/分鐘 梯度·· 20-50% B/30分鐘 [B] 5 0分鐘梯度〇〜80% 2 -丙醇水溶液,含〇·3% TFA 1亳升/分 鐘使用 LichrosorbR RP Select B(7 微米)25〇x4 毫米管柱 [C] 管柱: Lichrospher(5 微米)100RP8 125 X 4 亳米 溶離溶 A : 0.01 M Na phosphate pH 7.0 溶離液B : 0.005 M磷酸鈉pH 7.0/60%體積之2 -丙醇 流速·· 0.7毫升/分鐘 梯度·· 1-99% B/50分鐘。 質譜(MS) : EI(電子衝擊離子化)M + F A B (快速原子撞擊)(m+H) + DMPP -樹脂係表4 - ( 2 f,4 ’ -二甲氧苯基羥甲基)苯氧基-樹 脂[si c],即一種容許支鏈經保護之肽的合成之超級酸-不 穩定樹脂。 實例1 溶0.6克Fmoc-Lys(Boc )·〇Η於100毫升二氣甲烷,添加 1.2當量之DMPP-樹脂,1.4當量之HOBt與1.4當量之DCCI ,並於室溫下攪拌該混合物1 2小時。去除溶劑造成Fmoc-Lys(Boc )-DMPP-樹脂。在肽合成儀上,吾人使用超過三 倍量之經保護的脯胺酸令Fmoc-Pro-OH與H-Lys(BOC)- DMPP樹脂縮合[后者係經卩比淀/DMF(20%)自Fm〇c-Lys(BOC)-DMPP樹脂上釋出]。該偶合反應係以 -28- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁)
• IJ >裝----L---ITf 517063 經濟部中央標準局員工消費合作杜印製 A7 ____ B7 五、發明説明(26 ) DCCI/HOBt於室溫下進行。可得 Fmoc-Pro-Lys(BOC)· DMPP樹脂。類似地,后續切除F m 〇 c保護基及連續以 Fmoc-Ser(But)-OH,Fmoc-Asp(OBut)-OH,Fmoc-Gly-OH, Fmoc-Arg(Mtr)-OH,Fmoc-Gly-OH,Fmoc-Gly-OH,Fmoc-Gly-OH與Bit-OH進行偶合亦是在相同反應條件下,重覆 每一偶合反應 - 以吡啶/ D M F ( 2 0 % )釋出α -胺基 - 經二甲基乙醯胺洗之 -與Fmoc-胺基酸或Bit-OH進行反應 Bit-Gly-Gly-Gly-Arg(Mtr)-Gly-Asp(OBut)-Ser(But)-Pro-Lys(BOC)-DMPP-樹脂。 該樹脂經CF3S〇3H/CH2C12/H20洗之以生成Bit-Gly-Gly-Gly_Arg(Mtr)-Gly-Asp(OBut)-Ser(But)-Pro-Lys(BOC)-OH。 保護基以2N HC1以之二嘮烷溶液切除,若去除溶劑后便溶 殘渣於TFA/CH2C12並以Et20沈澱之,然后經RP-HPLC進 行純化。Bit-Gly-Gly-Gly-Arg-Gly-Asp-Ser-Pro-Lys-OH X 2 TFA ; RT [B]二 12.14 ; FAB 1056。 實例2 類似實例 1,連續以 Fmoc-Pro-OH,Fmoc-Cys(Trt)-OH, Fmoc-Asp(OBut)-OH,Fmoc-Ala-OH,Fmoc-Thr(But)-OH ,Fmoc-Lys(BOC)-OH ? Fmoc-Gly-OH ^ Fmoc-Gly-OH ? Fmoc-Gly-〇H 與 Bit-OH 偶合DMPP·樹脂生成: Bit-Gly-Gly-Gly-Lys(BOC)-Thr(But)-Ala-Asp(OBut)-Cys(Trt) __ —_-29- _ 本度適用中關家標準(CNS) A4規格(21GX297公羡) ~ (請先閲讀背面之注意事項再填寫本頁)
517063 A7 B7 五、發明説明(27) (請先閱讀背面之注意事項再填寫本頁) -Pro-DMPP-樹脂自樹脂切除,切除保護基並純化便生成 Bit-Gly-Gly-Gly-Lys-Thr-Ala-Asp-Cys(Trt)-Pro-OH x 2 TFA ; RT[B]27.6 ; FAB 1273。 下列化合物係藉類似方法藉其與DMPP -樹脂縮合而得: 與 Fmoc-Pro_OH,Fmoc_Cys(Trt)_OH,Fmoc_Asp(OBut)-OH, Fmoc-Ala-OH,Fmoc-Thr(But)-OH, Fmoc-Lys(BOC)-OH和 Bit-OH :
Bit-Lys-Thr_Ala-Asp-Cys(Trt)-Pro_OH;
與 Fmoc-Pro-OH,Fmoc-Cys(Trt)-OH,Fmoc-Asp(OBut)-OH, Fmoc-Ala-OH,Fmoc-Ala-OH,Fmoc-Lys(BOC)-OH和 Bit-OH
Bit-Lys-Ala-Ala-Asp-Cys(Trt)-Pro-OH ; 與 Fmoc-Pro-OH,Fmoc-Cys(Trt)-OH,Fmoc_Asp(OBut)_OH, Fmoc-Ala-OH,Fmoc_Thr(But)-OH,Fmoc-Arg(Mtr)-OH和 Bit-OH :
Bit-Arg-Thr-Ala-Asp-Cys(Trt)-Pro-OH ; 與 Fmoc_Pro-OH, Fmoc-Cys(Trt)_OH,Fmoc-Asp(OBut)-OH, Fmoc-Ala_〇H,Fmoc_Ser(But)-OH和 Bit-OH : 經濟部中央標準局員工消費合作社印製
Bit-Ser-Ala-Asp-Cys(Trt)-Pro-OH > 與 Fmoc-Pro-OH, Fmoc_Cys(Trt)_OH,Fmoc_Asp(OBut)-OH, Fmoc-Ala_〇H, Fmoc-Ser(But)-OH,Fmoc-Gln(Trt)-OH 和 Bit_ OH : ' Bit-Gln-Ser-Ala-Asp-Cys(Trt)-Pro-OH ; 與 Fmoc-Pro_OH,Fmoc-Cys(Trt)-OH,Fmoc-Asp(OBut)-OH, 30- 本紙張尺度適用中國國家標準(CNS ) M規格(210X 297公釐) 517063 A7 __B7 五、發明説明(28 )
Fmoc-Ala-OH,Fmoc-Ser(But)-OH,Fmoc-Glp-OH 和 Bit-OH (請先閲讀背面之注意事項再填寫本頁)
Bit-Glp-Ser-Ala-Asp-Cys(Trt)-Pro-OH ; 與FmocPro-OH,Fmoc-Cys(Trt)_OH,Fmoc-Gly_OH,Fmoc Ala-OH,Fmoc-Ser(But)-OH,Fmoc-Ile-OH 和 Bit_OH : Bit-Ile-Ser-Ala-Gly-Cys(Trt)-Pro-OH ; 與 Fmoc-Pro-OH,Fmoc-Cys(Trt)-OH,Fmoc-Gly-OH,Fmoc-Ala-OH,Fmoc-Ser(But)-OH,Fmoc-Arg(Mtr)-OH 和 Bit_OH : Bit-Arg-Ser-Ala-Gly-Cys(Trt)-Pro-OH ; 與 Fmoc-Pro-OH,Fmoc-Cys(Trt)_OH,FMOC-Asp(OBut)_OH, Fmoc-Gly-OH,Fmoc-Gly-OH,Fmoc-Lys(BOC)-OH 和 Bit-OH :
Bit-Lys-Gly-Gly-Asp-Cys(Trt)-Pro-OH ; 與 Fmoc-Cys(Trt)-OH,Fmoc-Asp(OBut)-OH,Fmoc-Ala-OH, Fmoc-Thr(But)_OH,Fmoc_Lys(BOC)_OH ^ Bit-OH : Bit-Lys_Thr-Ala-Asp-Cys(Trt)-OH ; 經濟部中央標準局員工消費合作社印製 與 Fmoc-Thr(But)-OH,Fmoc-Ala-OH,Fmoc-Pro-OH,Fmoc· Gly-OH? Fmoc-Lys(BOC)-OH, Fmoc-His(Trt)-OH, Fmoc-Pro-OH? Fmoc-Asn(Trt)-OH, Fmoc-Arg(Mtr)-OH? Fmoc-Pro-OH, Fmoc-Cys(Trt)-OH,Fmoc-Asp(OBut)_OH, Fmoc-Ala-OH和 Bit-OH : a)當以TF A及1 0 %硫酚切除保護基時可得:
Bit-Ala-Asp-Cys-Pro-Arg-Asn-Pro-His-Lys-Gly-Pro-Ala-Thr-OH ; -31 - 本紙張尺度適用中國國家標準(CNS ) A4規格(21 〇X 297公釐) "~ 517063 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明(29) b)當以TFA及1 0 %笨甲硫醚切除保護基時可得: Bit-Ala-Asp-Cys(Trt)-Pro-Arg-Asn-Pro-His-Lys-Gly-Pro-Ala-Thr-OH ; 與?111〇〇丁111*_作扯)-011,?111〇〇八1&-011,?111〇〇?1:〇-011,卩111〇〇01” OH, Fmoc-Lys(BOC)-OH, Fmoc-His(Trt)-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Arg(Mtr)-OH, Fmoc-Pro-OH, Fmoc-Cys(Trt)-OH, Fmoc-Asp(OBut)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Thr(But)-OH,Fmoc_Lys(BOC)-OH,Fmoc-Gly-OH和 Bit-OH : a) 當以TFA及1 0 %硫酚切除保護基時可得:
Bit-Gly-Ly s-Thr-Cy s-Asp-Cys-Pro-Arg-Asn-Pro-His-Lys-Gly-Pro-Ala-Thr-OH ; b) 當以TFA及10%笨甲硫醚切除保護基時可得: Bit-Gly-Lys-Thr-Cys(Trt)-Asp-Cys(Trt)-Pro-Arg-Asn-Pro-His-Lys-Gly-Pro-Ala-Thr-OH ; 與 Fmoc-Gly-OH,Fmoc-Lys(BOC)-OH,Fmoc_His(Trt)-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Arg(Mtr)-OH, Fmoc-Pro-OH, Fmoc-Cys(Trt)-OH, Fmoc-Asp(OBut)-OH? Fmoc-Ala-OH,Fmoc-Thr(But),OH,Fmoc-Lys(BOC)-OH和 Bit-OH : a) 當以TFA及1 0 %硫酚切除保護基時可得: Bit-Lys-Thr-Ala-Asp-Cys-Pro-Arg-Asn-Pro-His-Lys-Gly-OH ; b) 當以TFA及10%笨甲硫醚切除保護基時可得: -32- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁) _裝- 517063 A7 __B7 五、發明説明(30 )
Bit-Lys-Thr-Ala-Asp-Cys(Trt)-Pro-Arg-Asn-Pro-His-Lys-Gly-OH ; 與 Fmoc-Thr(But)-OH,Fmoc_Ala_OH,Fmoc-Pro-OH,Fmoc-Gly-OH,,Fmoc-Lys(BOC)-OH,Fmoc-His(Trt)-OH,Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH? Fmoc-Arg(Mtr)-OH? Fmoc-Pro-OH,Fmoc-Cys(Trt)-OH,Fmoc-Asp(OBut)-OH,Fmoc-Ala-OH, Fmoc-Thr(But)-OH,Fmoc-Lys(BOC)_OH和 Bit_OH : a) 當以TF A及1 0 %硫酚切除保護基時可得: Bit-Lys-Thr-Ala-Asp-Cys-Pro-Arg-Asn-Pro-His-Lys-Gly-Pro-Ala-Thr-OH ; b) 當以TF A及1 0 %苯甲硫醚切除保護基時可得: Bit-Lys-Thr-Ala-Asp-Cys(Trt)-Pro-Arg-Asn-Pro-His-Lys-Gly-Pro-Ala-Thr-OH ; 與 Fmoc-Gly-OH, Fmoc-Lys(BOC)_OH, Fmoc-His(Trt)-OH, Fmoc_Pro-OH,Fmoc-Asn(Trt)_OH,Fmoc-Arg(Mtr)-OH, Fmoc-Pro-OH,Fmoc-Cys(Trt)-OH,Fmoc-Asp(OBut)-OH, Fmoc-Ala-OH,Fmoc-Thr(But)-OH,Fmoc-Lys(BOC)-OH, Fmoc-Gly-OH 和 Bit-OH : 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) a) 當以TF A及1 0 %硫酚切除保護基時可得: B it-Gly-Ly s - Thr-Ala-A sp - Cy s - Pr 〇 - Arg-A sn-Pro-His-Lys-Gly-OH ; b) 當以TFA及10%苯甲硫醚切除保護基時可得: Bit-Gly-Lys-Thr-Ala-Asp-Cys(Trt)-Pro-Arg-Asn-Pro-His-Lys-Gly-OH ; -33- 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) 517063 A7 ____B7 五、發明説明(31 ) 與 Fmoc_Thr(But)-OH,Fmoc-Ala_OH,Fmoc-Pro-OH,Fmoc-Gly-OH, Fmoc-Lys(BOC)-OH, Fmoc-His(Trt)-OH , Fmoc-Pro_OH,Fmoc-Asn(Trt)-OH,Fmoc-Arg(Mtr)-OH,Fmoc-Pro-OH,Fmoc-Cys(Trt)-OH,Fmoc-Asp(OBut)_OH,Fmoc-Ala-OH, Fmoc-Thr(But)-OH和 Bit-OH :
Bit-Thr-Ala-Asp-Cys-Pro-Arg-Asn-Pro-His-Lys-Gly-Pro-Ala-Thr-OH ; 與 Fmoc-Thr(But)-OH,Fmoc-Ala-OH,Fmoc-Pro_OH,Fmoc-Gly-OH, Fmoc-Lys(BOC)-OH, Fmoc-His(Trt)-OH , Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Arg(Mtr)-OH? Fmoc-Pro-OH,Fmoc-Cys(Trt)-OH,Fmoc-Asp(OBut)-OH,Fmoc-Ala-OH 和 Bit-OH :
Bit-Ala-Asp-Cys-Pro-Arg-Asn-Pro-His-Lys-Gly-Pro-Ala-Thr-OH ; 與 Fmoc-Gly-OH,FmooLys(BOC)-OH,Fmoc-His(Trt)-OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Arg(Mtr)-OH, Fmoc-Pro-OH, Fmoc-Cys(Trt)-OH, Fmoc-Asp(OBut)-OH, Fmoc-Ala_OH和 Bit-OH : 經濟部中央標準局員工消費合作社印製 (請先閲讀背面之注意事項再填寫本頁)
Bit-Ala-Asp-Cys-Pro-Arg-Asn-Pro-His-Lys-Gly-OH ; 與 Fmoc_Pro_〇H,Fmoc_Asn(Trt)-OH,Fmoc-Arg(Mtr)_OH, Fmoc-Pro-OH? Fmoc-Cys(Trt)-OH, Fmoc-Asp(OBut)-OH, Fmoc-Ala-OH, Fmoc-Thr(But)-OH,Fmoc-Lys(BOC)-OH和 Bit-OH :
Bit-Lys-Thr-Ala-Asp-Cys(Trt)-Pro-Arg-Asn-Pro-OH ; __ -34- 本^張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) """ 經濟部中央標準局員工消費合作社印製 517063 A7 __B7 五、發明説明(32 ) 與 Fmoc_Lys(BOC)-OH,Fmoc-His(Trt)_OH,Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Arg(Mtr)-OH, Fmoc-Pro-OH, Fmoc-Cys(Trt)_OH,Fmoc-Asp(OBut),OH,Fmoc-Ala-OH, Fmoc-Thr(But)-OH,Fmoc_Lys(BOC)-OH和 Bit-OH :
Bit-Lys-Thr-Ala-Asp-Cys(Trt)-Pro-Arg-Asn-Pro-His-Lys-OH ; 與 Fmoc-His(Trt)-OH,Fmoc-Pro-OH,Fmoc-Asn(Trt)-OH, Fmoc-Arg(Mtr)-OH, Fmoc-Pro-OH, Fmoc-Cys(Trt)-OH, Fmoc-Asp(OBut)-OH, Fmoc-Ala-OH, Fmoc-Thr(But)-OH, Fmoc-Lys(BOC)-OH和 Bit-OH :
Bit-Lys-Thr-Ala-Asp-Cys(Trt)-Pro-Arg-Asn-Pro-His-OH ; 與 Fmoc_Arg(Mtr)-OH,Fmoc-Pro-OH,Fmoc-Cys(Trt)_OH, Fmoc-Asp(OBut)-OH? Fmoc-Ala-OH? Fmoc-Thr(But)-OH? Fmoc-Lys(BOC)-OH和 Bit-OH :
Bit-Lys-Thr-Ala-Asp-Cys(Trt)-Pro-Arg-OH ; 與 Fmoc-Lys(BOC)-OH,Fmoc-His(Trt)-OH,Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Arg(Mtr)-OH, Fmoc-Pro-OH, Fmoc-Cys(Trt)-OH,Fmoc-Asp(OBut)-OH和 Bit-OH :
Bit-Asp-Cys(Trt)-Pro-Arg-Asn-Pro-His-Lys-OH ; 與 Fmoc_Arg(Mtr)_OH,Fmoc_Pro-OH,Fmoc-Cys(Trt)-OH, Fmoc-Asp(OBut)-OH,Fmoc-Ala-OH和 Bit-OH ·· Bit-Ala-Asp-Cys(Trt)-Pro-Arg-OH ; 與 Fmoc-Arg(Mtr)-OH,Fmoc-Pro_OH,Fmoc,Cys(Trt)-OH, _____-35-_ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先聞讀背面之注意事項再填寫本頁)
經濟部中央標準局員工消費合作社印製 517063 A7 _ B7 五、發明説明(33 )
Fmoc-Asp(OBut)-OH,Fmoc-Ala-OH,Fmoc-Thr(But)_OH和 Bit_OH :
Bit-Thr-Ala-Asp-Cys(Trt)-Pro-Arg-OH ; 與 Fmoc-Pro-OH,Fmoc-Cys(Trt)-OH,Fmoc_Asp(OBut)-OH, Fmoc-Ala-OH,Fmoc-Thr(But)_OH,Fmoc-Lys(B〇C)-〇H和 Bit-OH :
Bit-Lys-Thr-Ala-Asp-Cys(Trt)-Pro-OH ; 與 Fmoc-NMeAla_OH,Fmoc-Cys(Trt)-OH,Fmoc-Asp(OBut)-OH,Fmoc-Ala-OH,Fmoc-Thr(But)-OH,Fmoc-Lys(BOC)-OH 和 Bit-OH :
Bit-Lys-Thr-Ala-Asp-Cys(Trt)-NMeAla-OH 實例3 ' 將1.7克不貴的( + )_生物素-N-琥珀亞醯胺基[原文如此] 酯與 0.5 克三乙胺加至 3.05 克環-(Arg-Gly_Asp-D-Phe_Lys)[ 經環化 H-Arg(Mtr)-Gly-Asp(OBut)-D-Phe-Lys(BOC)-OH 成 環-(Arg(Mtr)-Gly-Asp(OBut)-D-Phe-Lys(BOC))並於其后切 除保護基而得]之100毫升二氯甲烷的溶液中。室溫中攪拌 該混合物5小時,而通常調整步驟可生成環-(A r g · G1 y -
Asp-D-Phe-Lys(Ne-Bit))xTFA;RT[B]11.32;FAB 830。 實例4 以類似實例3的方法,可自3.05克環-(Arg-Gly-Asp_D-Phe-Lys)與2.3克N -琥珀亞醯胺基(+) -生物素-6-胺基己酯 ("A”)(其可自市面上便宜購得)與〇.5克三乙胺得到環“八%· Gly-Asp-D-Phe-Lys(N ε -Bit-Aha )) x TFA ; RT [C] 23.67 ; FAB 943 __ -36- 本紙張尺度適用中國國家標準(CNS ) A4規格(2丨Οχ 297公釐) " (請先閲讀背面之注意事項再填寫本頁)
經濟部中央標準局員工消費合作社印製 517063 A7 B7 五、發明説明(34 ) 亦可由類似方法經’’ A ”得到下列化合物 環-(Arg-Gly_Asp-D-Trp-Lys) 環-(Arg-Gly-Asp-D_Tyr-Lys) 環-(Arg-Gly-Asp-D-Phe-D-Lys) 環-(Arg_Gly-Asp-D-Phe-Cys) 環-(Arg-Gly-Asp-D-Phe_Dab) 環 _ (Arg_Gly-Asp-D-Trp-D-Cys) 環 _ (Arg_Gly-Asp-D-Tyr-D-Cys) 環-(Arg-Gly-Asp-Phe,D-Lys) 環-(Arg-Gly-Asp-Trp,D-Lys) 環 (Arg-Gly-Asp-Tyr-D-Lys) 環 _ (Arg_Gly-Asp-Phe,D-Cys) 環-(Arg-Gly-Asp-Phe-Dab) 環-(Arg-Gly-Asp-Trp-D-Cys) 環-(Arg-Gly-Asp-Tyr-D-Cys) 環-(Arg-Gly-Asp-D-Trp-Orn) 環-(Arg-Gly-Asp-D-Tyr-Orn) 環-(Arg-Gly-Asp-D-Phe-Orn) 環 (Arg-Gly-Asp-D-Trp-D-Orn) 環 _ (Arg-Gly-Asp-D-Tyr-D-Orn) 環-(Arg-Gly-Asp-D-Phe-D-Orn) 環-(Arg-Gly-Asp-D-Trp-Dab) 環 (Arg-Gly-Asp-D-Tyr-Dab) -37- 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) (請先閲讀背面之注意事項再填寫本頁)
517063 經濟部中央標準局員工消費合作社印製 A7 B7五、發明説明(35 ) 環 (Arg-Gly-Asp-D-Trp_Dap) 環-(Arg-Gly-Asp-D-Tyr-Dap) 環-(Arg-Gly-Asp-D-Phe-Dap) 環-(Arg-Gly-Asp-D-Trp-D-Dap) 環-(Arg-Gly-Asp-D-Tyr-D-Dap) 環-(Arg-Gly_Asp-D-Phe-D-Dap) 下列化合物 環-(Arg-Gly-Asp-D-Trp-Lys(N ε -Bit-Aha)) 環-(Arg-Gly-Asp-D_Tyr_Lys(N ε -Bit-Aha)) 環-(Arg-Gly-Asp-D-Phe-D-Lys(N ε -Bit-Aha)) 環-(Arg-Gly-Asp-D-Phe-Cys(S-Bit-Aha)) 環 (Arg-Gly-Asp-D-Phe-Dab(N,-Bit-Aha)) 環 (Arg-Gly-Asp-D-Trp-D-Cys(S-Bit-Aha)) 環-(Arg-Gly_Asp_D-Tyr-D-Cys(S-Bit-Aha)) 環-(Arg-Gly-Asp-Phe-D-Lys(N ε -Bit-Aha)) 環 (Arg-Gly-Asp-Trp-D-Lys(N ε -Bit-Aha)) 環-(Arg-Gly-Asp-Tyr-D-Lys(N ε -Bit-Aha)) 環-(Arg-Gly-Asp-Phe-D-Cys(S-Bit-Aha)) 環-(Arg-Gly-Asp-Phe-Dab(N,-Bit-Aha)) 環 (Arg-Gly-Asp-Trp-D-Cys(S-Bit-Aha)) 環-(Arg-Gly-Asp-Tyr-D-Cys(S-Bit-Aha)) 環-(Arg-Gly-Asp-D-Trp-Orn(N 0 -Bit-Aha)) 環-(Arg-Gly-Asp-D-Tyr-Orn(N a -Bit-Aha)) 環-(Arg-Gly-Asp-D-Phe-Orn(N 4 -Bit-Aha)) -38- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) mafl will —·Βϋ n·^— I— 1^1 m Hi ♦ 0 (請先閱讀背面之注意事項再填寫本頁) 訂
-IM 517063 A7 _____B7 五、發明説明(36 ) 環-(Arg-Gly-Asp-D-Trp-D-Orn(N θ -Bit-Aha)) 環-(Arg-Gly-Asp-D-Tyr-D-Orn(N $ -Bit-Aha)) 環-(Arg-Gly-Asp-D-Phe-D-Orn(N a -Bit-Aha)) 環-(Arg-Gly-Asp-D-Trp-Dab(N r _Bit-Aha)) 環-(Arg-Gly-Asp-D-Tyr-Dab(N,-Bit-Aha)) 環 _ (Arg-Gly-Asp_D_Trp-Dap(N々 - Bit>Aha)) 環-(Arg-Gly-Asp-D-Tyr-Dap(NA -Bit-Aha)) 環 (Arg-Gly-Asp-D-Phe-Dap(N々 -Bit-Aha)) 環-(Arg-Gly-Asp-D-Trp-D-Dap(N 々-Bit-Aha)) 環 (Arg-Gly-Asp-D-Tyr-D-Dap(N々 -Bit-Aha)) 環-(Arg-Gly-Asp-D-Phe-D-Dap(NA -Bit-Aha)) 實例5 將6克Boc-Aha N_琥珀亞醯胺基酯加入3.05克環-(八%-Gly-Asp-D_Phe-Lys)之40 毫升 5% NaHC03及40 毫升 THF 溶 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 液中。攪拌4小時並經通常調整步驟可生成環-(入巧_01严 Asp-D-Phe-Lys(BOC-Aha)),RT [C] 27.7,FAB 817。在 H C 1 /二哼烷中切除Β Ο C基並經通常調整步驟可生成環-(Arg-Gly-Asp-D-Phe-Lys(Ns -Aha))x 2 TFA,RT [C] 14.76, FAB 717 〇 以類似實例1方法,后續與(+ )-生物素-Ν -琥珀亞醯胺基 [原文如此]醋反應
Bit-Aha))x 2 TFA,RT [C] 23.67,FAB 943。 實例6 以類似實例4方法可自環_(Arg-Gly-Asp-D_Phe-Lys_Gly) ____-39- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 517063 A7 B7 五、發明説明(37) (請先閱讀背面之注意事項再填寫本頁) 經環化 H-Arg(Mtr)-Gly-Asp(OBut)-D-Phe-Lys(BOC)-Gly-OH 成環-(Arg(Mtr)-Gly-Asp(OBut)_D-Phe_Lys(BOC)_Gly)並於 其后切除保護基而得]與N -琥珀亞醯胺基(+)生物素基-6 -胺基己酯得到環-(Arg_Gly-Asp-D-Phe-Lys(N “Bit-Aha)_Gly) x TFA,RT [A] 10.97,FAB 1000 0 以類似方法可自環-(Arg-Gly-Asp-D-Phe-Val-Lys)[經環化 H-Arg(Mtr)-Gly-Asp(OBut)-D-Phe-Val-Lys(BOC)-OH成環-(Arg(Mtr)_Gly-Asp(OBut)-D_Phe-Val-Lys(BOC))並於其后切 除保護基而得]與N _琥珀亞醯胺基(+)生物素基 6 -胺基己 酉旨得到環-(Arg-Gly-Asp-D-Phe-Val-Lys(N S-Bit-Aha)) X TFA ,RT [A] 16.11,FAB 1042。 以類似方法可自環-(Arg-Gly_Asp-D-Phe-N-Me-Lys)與 N -琥珀亞S&胺基(+)生物基-6 -胺基己酯得到環-(Arg-Gly-Asp-D-Phe-N-Me_Lys(N ε -Bit_Aha)) 〇 實例7 經濟部中央標準局員工消費合作社印製 以類似實例1方法,經添加1.4當量HOBt與1.4當量DCCI ,以下列化合物連續偶合至MBHA樹脂:m&Fmoc-Pro-OH,Fmoc-Cys(Trt)-OH,Fmoc-Asp(OBut)_OH,Fmoc-Ala-OH, Fmoc-Thr(But)-OH, Fmoc-Lys(BOC)-OH? Fmoc-Gly-OH? Fmoc-Gly-OH與 Bit-OH生成:
Bit-Gly-Gly-Gly-Lys(BOC)-Thr(But)-Ala-Asp(OBut)-Cys(Trt) -Pro-MBHA·樹脂經T F A將之自樹脂切出,以吡啶/ D M F去 保護基並純化生成
Bit-Gly-Gly-Gly-Lys-Thr-Ala-Asp-Cys(Trt)-Pro-NH2 -40- :尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 經濟部中央標準局員工消費合作社印製 517063 A7 ____B7 _ 五、發明説明(38 ) 以類似方法,藉由縮合MBHA ·樹脂 與 Fmoc-Pro_OH,Fmoc-Cys(Trt)-OH,Fmoc-Asp(OBut)-OH, Fmoc-Ala_OH, Fmoc-Thr(But)-OH, Fmoc_Lys(BOC)-OH 和 Bit-OH可得:
Bit-Lys-Thr-Ala-Asp-Cys(Trt)-Pro-NH2 »
與 Fmoc-Pro-OH,Fmoc-Cys(Trt)_OH,Fmoc-Asp(OBut)-OH, Fmoc-Ala-OH,Fmoc-Ala_OH,Fmoc-Lys(BOC)-OH和 Bit-OH 可仔:
Bit-Lys-Ala-Ala-Asp-Cys(Trt)_Pro-NH2 ; 與 Fmoc_Pro_OH,Fmoc-Cys(Trt)-OH,Fmoc-Asp(OBut)_OH, Fmoc-Ala-OH,Fmoc-Thr(But)-OH, Fmoc-Arg(Mtr)_OH 和 Bit-OH可得:
Bit-Arg_Thr-Ala-Asp_Cys(Trt)_Pro_NH2 ; 與 Fmoc-Pro-OH,Fmoc_Cys(Trt)-OH,Fmoc-Asp(OBut)_OH, Fmoc_Ala-OH,Fmoc_Ser(But)-OH和 Bit-OH 可得: Bit-Ser_Ala-Asp-Cys(Trt)-Pro-NH2 ; 與 Fmoc-Pro-OH,Fmoc-Cys(Trt)-OH,Fmoc_Asp(OBut)-OH, Fmoc-Ala-OH,Fmoc-Ser(But)-OH,Fmoc-Gln(Trt)_OH 和 Bit-OH可得:
Bit-Gln-Ser-Ala-Asp_Cys(Trt)_Pro-NH2 ;
與 Fmoc-Pro-OH,Fmoc-Cys(Trt)-OH,Fmoc_Asp(OBut)_OH, Fmoc_Ala-OH,Fmoc-Ser(But)_OH,Fmoc-Glp-OH 和 Bit-OH 可得:
Bit-Glp-Ser-Ala-Asp-Cys(Trt)-Pro-NH2 ? 41 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) ' (請先閲讀背面之注意事項再填寫本頁) Ϊ· 訂 517063 A7 _____B7 五、發明説明(39 ) 與?111〇。-?1*〇-011,卩111〇〇€>^(111'1:)_011,卩111〇〇01丫-011,?111〇。-Ala_OH,Fmoc-Ser(But)-OH,Fmoc_Ile-OH 和 Bit-OH 可得: Bit-Ile-Ser-Ala-Gly-Cys(Trt)-Pro-NH2 ; 與 Fmoc-Pro_OH,Fmoc-Cys(Trt)_OH,Fmoc_Gly_OH,Fmoc-Ala-OH,Fmoc-Ser(But)-OH,Fmoc_Arg(Mtr)-OH 和 Bit-OH 可 得:
Bit_Arg-Ser-Ala-Gly-Cys(Trt)-Pro-NH2 ;
與 Fmoc-Pro-OH,Fmoc_Cys(Trt)_OH,Fmoc-Asp(OBut)-OH, Fmoc-Gly_OH,Fmoc-Gly-OH,Fmoc-Lys(BOC)-OH和 Bit-OH 可得:
Bit-Lys_Gly-Gly-Asp-Cys(Trt)-Pro-NH2 ; 與 Fmoc-Cys(Trt)-OH,Fmoc-Asp(OBut)-OH,Fmoc-Ala-OH, Fmoc-Thr(But),OH,Fmoc-Lys(BOC)_OH和 Bit-OH 可得: Bit_Lys_Thr-Ala_Asp-Cys(Trt)_NH2 ; 經濟部中央標準局員工消費合作社印製 t---L------•裝-- 4 t (請先閲讀背面之注意事項再填寫本頁) 與 Fmoc-Thr(But)-OH,Fmoc-Ala-OH,Fmoc-Pro-OH,Fmoc-Gly-OH,,Fmoc-Lys(BOC)-OH,Fmoc_His(Trt)-OH,Fmoc-Pro-OH,Fmoc-Asn(Trt)-OH, Fmoc-Arg(Mtr)-OH, Fmoc-Pro-OH, Fmoc-Cys(Trt)-OH? Fmoc-Asp(OBut)-OH, Fmoc-Ala-OH 和 Bit_OH ·_ a) 當以TFA及1 0 %硫酚切除保護基時可得; Bit-Ala-Asp-Cys-Pro-Arg-Asn-Pro-His-Lys-Gly-Pro-Ala-Thr-NH2 ; b) 當以TFA及1 0 %笨甲硫醚切除保護基時可得·· Bit-Ala-Asp-Cys(Trt)-Pro-Arg-Asn-Pro,His-Lys-Gly- -42- 本&尺度適用中國國家標準(CNS ) A4規格(210X297公釐) — 517063 A7 ____B7_ 五、發明説明(4〇 )
Pro-Ala_Thr_NH2 ; 與 Fmoc-Thr(But)-OH,Fmoc_Ala-OH,Fmoc-Pro,OH, Fmoc-Gly-OH? , Fmoc-Lys(BOC)-OH? Fmoc-His(Trt)-OH? Fmoc-Pro-OH? Fmoc-Asn(Trt)-OH, Fmoc-Arg(Mtr)-OH? Fmoc-Pro-OH,Fmoc-Cys(Trt)-OH,Fmoc-Asp(OBut)-OH,Fmoc-Cys(Trt)-OH,Fmoc-Thr(But)-OH,Fmoc-Lys(BOC)-OH, Fmoc-Gly-OH和 Bit-OH : a) 當以TF A及1 0 %硫酚切除保護基時可得:
Bit-Gly-Lys-Thr-Cys-Asp-Cys-Pro-Arg-Asn-Pro-His-Lys_Gly-Pro-Ala-Thr-NH2 ; b) 當以TFA及1 0 %笨甲硫醚切除保護基時可得: Bit-Gly-Lys-Thr-Cys(Trt)-Asp-Cys(Trt)-Pro-Arg-Asn-Pro-His-Lys_Gly-Pro-Ala-Thr_NH2 ; 與 Fmoc_Gly-OH,,Fmoc-Lys(BOC)-OH,Fmoc_His(Trt)_OH, Fmoc-Pro-OH,Fmoc-Asn(Trt)-OH,Fmoc-Arg(Mtr)-OH, Fmoc-Pro-OH, Fmoc-Cys(Trt)-OH, Fmoc-Asp(OBut)-OH, Fmoc-Ala-OH, Fmoc-Thr(But)-OH,Fmoc-Lys(BOC)-OH 和 Bit-OH : 經濟部中央標準局員工消費合作社印製 t—„------— (請先閱讀背面之注意事項再填寫本頁) a) 當以TF A及1 0 %硫酚切除保護基時可得:
Bit-Lys-Thr-Ala-Asp-Cys-Pro-Arg-Asn-Pro-His-Lys-Gly- NH2 ; b) 當以TFA及10%笨甲硫醚切除保護基時可得:_ Bit-Lys-Thr-Ala-Asp-Cys(Trt)-Pro-Arg-Asn-Pro-His-Lys-Gly-NH2 ; ___-43-___ 冢紙張尺度適用中國國家標準(CNS ) A4規格(21 OX 297公釐) 517063 A7 ____B7__ 五、發明説明(41 ) (請先閱讀背面之注意事項再填寫本頁) 與 Fmoc-Thr(But)-OH,Fmoc-Ala-OH,Fmoc-Pro-OH,Fmoc-Gly-OH,Fmoc-Lys(BOC)-OH,Fmoc-His(Trt)-OH,Fmoc-Pro-〇H5 Fmoc-Asn(Trt)-OH, FMoc-Arg(Mtr)-OH? Fmoc-Pro-OH, Fmoc-Cys(Trt)-OH, Fmoc-Asp(OBut)-OH, Fmoc-Ala-OH, Fmoc-Thr(But)-OH,Fmoc-Lys(BOC)-OH和 Bit-OH : a) 當以TFA及1 0 %硫酚切除保護基時可得: Bit-Lys-Thr-Ala-Asp-Cys-Pro-Arg-Asn-Pro-His-Lys-Gly-Pro-Ala-NH2 ; b) 當以TFA及10%笨甲硫醚切除保護基時可得: Bit-Lys-Thr-Ala-Asp-Cys(Trt)-Pro-Arg-Asn-Pro-His-
Lys-Gly-Pro-Ala-Thr-NH2 » 與 Fmoc,Gly-OH, Fmoc-Lys(BOC)-OH,Fmoc_His(Trt)_OH, Fmoc_Pro-OH, Fmoc_Asn(Trt)_OH,FMoc_Arg(Mtr)-OH, Fmoc-Pro-OH, Fmoc-Cys(Trt)-OH, Fmoc-Asp(OBut)-OH? Fmoc-Ala-OH, Fmoc-Thr(But)-OH, Fmoc-Lys(BOC)-OH? Fmoc_Gly-OH和 Bit-OH : a) 當以TFA及10%硫酚切除保護基時可得: Bit-Gly-Lys-Thr-Ala-Asp-Cys-Pro-Arg-Asn-Pro-His-Lys 瞒 經濟部中央標準局員工消費合作社印製
Gly-NH2 ; b) 當以TFA及1 0 %笨甲硫醚切除保護基時可得: Bit-Gly-Lys-Thr-Ala-Asp-Cys(Trt)-Pro-Arg-Asn-Pro-His_Lys-Gly-NH2 ; 與 Fmoc-Thr(But)-OH,Fmoc-Ala-OH,Fmoc_Pro_OH,Fmoc-Gly-OH,Fmoc-Lys(BOC)-OH,Fmoc-His(Trt)-OH,Fmoc-Pro· _ -44- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 517063 A7 B7 五、發明説明(42 ) OH? Fmoc-Asn(Trt)-OH9 Fmoc-Arg(Mtr)-OH, Fmoc-Pro-OH, Fmoc-Cys(Trt)-OH,Fmoc-Asp(OBut)-OH,Fmoc-Ala-OH, Fmoc-Thr(But)-OH和 Bit-OH 可得:
Bit-Thr-Ala-Asp-Cys-Pro-Arg-Asn-Pro-His-Ly s-Gly-Pro-Ala_Thr-NH2 ; 與 Fmoc-Thr(But)-OH,Fmoc-Ala-OH,Fmoc_Pro-OH,Fmoc-Gly-OH,Fmoc_Lys(BOC)_OH,Fmoc-His(Trt)-OH,Fmoc-Pro· OH, Fmoc-Asn(Trt)-OH? Fmoc-Arg(Mtr)-OH, Fmoc-Pro-OH? Fmoc-Cys(Trt)-OH,Fmoc-Asp(OBut)_OH,Fmoc-Ala-OH和 Bit-OH可得:
Bit-Ala-Asp-Cys-Pro-Arg-Asn-Pro-His-Lys-Gly-Pro-Ala-Thr-NH2 ; 與 Fmoc-Gly-OH,Fmoc-Lys(BOC)-OH, Fmoc_His(Trt)_OH, Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH? Fmoc-Arg(Mtr)-OH, Fmoc-Pro-OH, Fmoc-Cys(Trt)-OH, Fmoc-Asp(OBut)-OH, Fmoc,Ala-OH和 Bit_OH 可得:
Bit>Ala-Asp-Cys_Pro-Arg-Asn_Pro-His_Lys_Gly-NH2 ; 經濟部中央標準局員工消費合作社印製 (請先聞讀背面之注意事項再填寫本頁) 與 Fmoc-Pro-OH,Fmoc-Asn(Trt)-OH,Fmoc-Arg(Mtr)-OH, Fmoc-Pro-OH,Fmoc-Cys(Trt)-OH,Fmoc-Asp(OBut)-OH, Fmoc-Ala-OH,Fmoc-Thr(But)-OH,Fmoc_Lys(BOC)-OH和 Bit-OH可得:
Bit-Lys-Thr-Ala-Asp-Cys(Trt)-Pro-Arg-Asn-Pro-NH2 ; 與 FmooLys(BOC)-OH,Fmoc_His(Trt)-OH,Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH? Fmoc-Arg(Mtr)-OH, Fmoc-Pro-OH, -45 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 經濟部中央標準局員工消費合作社印製 517063 A7 B7 五、發明説明(43 )
Fmoc-Cys(Trt)-OH,Fmoc-Asp(OBut)-OH,Fmoc-Ala-OH, Fmoc-Thr(But)-OH,Fmoc_Lys(BOC)-OH和 Bit-OH 可得:
Bit-Lys-Thr-Ala-Asp-Cys(Trt)-Pro-Arg-Asn-Pro-His-Lys-NH2 ; 與 Fmoc-His(Trt)-OH,Fmoc-Pro_OH,Fmoc-Asn(Trt),OH, Fmoc-Arg(Mtr)-OH, Fmoc-Pro-OH, Fmoc-Cys(Trt)-OH, Fmoc-Asp(OBut)-OH,Fmoc-Ala-OH,Fmoc-Thr(But)-OH, Fmoc-Lys(BOC)-OH和 Bit-OH 可得:
Bit-Lys-Thr-Ala-Asp-Cys(Trt)-Pro-Arg-Asn-Pro-His-NH2 » 與 Fmoc_Arg(Mtr)-OH, Fmoc-Pro-OH,Fmoc-Cys(Trt)-OH, Fmoc-Asp(OBut)-OH, Fmoc-Ala-OH, Fmoc-Thr(But)-OH, Fmoc-Lys(BOC)-OH和 Bit-OH 可得:
Bit-Lys-Thr_Ala-Asp_Cys(Trt)-Pro_Arg-NH2 ; 與 Fmoc-Lys(BOC)-OH,Fmoc-His(Trt)-OH,Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH? Fmoc-Arg(Mtr)-OH, Fmoc-Pro-OH, Fmoc-Cys(Trt)-OH,Fmoc-Asp(OBut)-OH和 Bit-OH 可得: Bit_Asp-Cys(Trt)-Pro-Arg-Asn-Pro-His_Lys-NH2 ; 與 Fmoc-Arg(Mtr)_OH,Fmoc-Pro_OH5 Fmoc_Cys(Trt)-OH, Fmoc-Asp(OBut)-OH,Fmoc,Ala-OH和 Bit_OH 可得: Bit-Ala-Asp-Cys(Trt)-Pro-Arg-NH2 ; 與 Fmoc-Arg(Mtr)-OH, Fmoc-Pro-OH,Fmoc-Cys(Trt)-OH, Fmoc-Asp(OBut)-OH,Fmoc-Ala-OH,Fmoc-Thr(But)-OH和 Bit-OH可得:
Bit_Thr-Ala-Asp_Cys(Trt)-Pro_Arg-NH2 ; -46- 本ϋ尺度適用中國國家標準(CNS ) A4規格(21 OX 297公釐) L----Γ—-----•裝-- (請先閲讀背面之注意事項再填寫本頁) 訂 517063 A7 B7 五、發明説明(44 ) 與 Fmoc_pr〇_〇H Fmoc-Cys(Trt)-OH,Fmoc-Asp(OBut)-OH, Fmoc_Ala_〇H,Fmoc_Thr(But)-OH,Fmoc-Lys(BOC)-OH和 Bit-OH可得:
Bit-Lys-Thr-Ala-Asp-Cys(Trt)-Pro-NH2 ; 與 Fmoc-NMeAla-OH,Fmoc-Cys(Trt)-OH,Fmoc_Asp(OBut)_OH, Fmoc-Ala-OH,Fmoc-Thr(But)-OH,Fmoc-Lys(BOC)-OH 和 Bit-OH可得:
Bit_Lys_Thr,Ala-Asp-Cys(Trt)-NMeAla-NH2 ; 實例8 適於充做親和力色析以純化整合素之物質的生產情形: 瓊脂的活化法如Lit. 1,1 4頁所示。然后將2 0毫克抗生 物素蛋白之2 0毫升的0.1 Μ碳酸氫鈉溶液加至1 0克的活化 瓊脂。 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 於4 °攪拌該懸浮液1 2小時並洗之。然后懸浮該物質於 添加以一些疊氮化鈉結晶的水中。含根據本發明之生物素 化化合物,例如環-(Arg-Gly-Asp-D-Phe-Lys(N ε -Bit))x T F A之抗生物素蛋白錯合物係藉由溶解1.1當量之肽於乙 酸鈉緩衝液,將該溶液加至抗生物素蛋白瓊脂之懸浮液並 於4 °C攪拌1 〇小時而形成。過量的肽則沖洗去除。 下列實例係關於醫藥製劑: 實例A :小瓶 以2N氫氯酸調1〇〇克式I之有效物質及5克轉酸氫二鈉的 3升去離子水溶液至pH 6.5過濾除菌,分裝至小瓶並冷凍 乾燥’然后於無菌條件下密封之。每一小瓶包含5毫克活 -47- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 517063 Α7 Β7 五、發明説明(45 ) 性物質。 實例B:栓劑 (請先閱讀背面之注意事項再填寫本頁) 熔化2 0克式I之活性物質和100克大豆卵磷質與1400克可 可油脂之混合物,倒入鑄模,令其冷却。每栓劑包含2 0毫 克活性物質。 實例C :溶液 由1克之式I活性物質,9.38克NaH2P〇4 · 2H20,28.48 克Na2HP04 · 12H20及0.1克之氯化芊鑌940毫升去離子水 製成溶液。調p Η至6.8體積成1升,並放射線照射滅菌。 此溶液可以眼藥水型式供應。 貫例D :油膏 無菌條件下混合500毫克式I之活性物質與9 9.5克之石油 壤。 實例Ε :錠劑 以傳統方法將1公斤之式I活性物質,4公斤乳糖,1.2公 斤馬鈐薯澱粉,0.2公斤滑石粉及〇· 1公斤硬脂酸鎂壓縮成 錠劑使每一錠劑包含1 0毫克活性物質。 實例F:塗覆錠劑 經濟部中央標準局員工消費合作社印製 以類似實例Ε的方法壓縮錠劑,然后以傳統方式供給含 蔗糖,馬鈐薯澱粉,滑石粉,黃耆膠與色素之塗覆物。 實例G :膠囊 以傳統方式包裝2公斤之式I活性物質於硬明膠膠囊,使 每一膠囊包含2 0毫克活性物質。 -48- 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) 517063 A7 _______B7 五、發明説明(46 ) 實例Η :安瓶 過遽滅菌1公斤式I活性物質之6 0升去離子水的溶液懸浮 於安瓶中並冷滚乾燥,然后於無菌條件下密封。每一安瓶 包括1 0毫克活性物質。 實例I :吸入噴劑 溶1 4克式I活性物質於1 0升等張的NaC 1溶液中,並以, 筒裝置將該溶液充填入市售噴霧容器中。該溶液可噴入口 或鼻中。一噴(約0· 1毫升)相當於約〇. 14毫克的劑量。 (請先閲讀背面之注意事項再填寫本頁} ^^衣· 經濟部中央標準局員工消費合作社印製 -49- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐)
Claims (1)
- 修正 本年月3 補充9〇ug A B c D517063 第85108686號專利申請案 中文申請專利範圍修正本(90年12月) 六、申請專利範圍 1..一種化合物,係選自下列之群: Bit-Gly-Gly-Gly-Arg-Gly-Asp-Ser-Pro-Lys-OH, Bit-Gly-Gly-Gly-Lys-Thr-Ala-Asp-Cys(Trt)-Pro-OH, 環-(Arg-Gly-Asp-D-Phe-Lys(Ns-Bit)), 環-(Arg-Gly-Asp-D-Phe-Lys(Ns-Aha)), 環-(Arg-Gly-Asp-D-Phe-Lys(N、Bit-Aha)-Gly), 環-(Arg-Gly-Asp-D-Phe-Val-Lys(N、Bit-Aha)), 環-(Arg-Gly-Asp-D-Phe-Lys(Ns-Bit-Aha)), 環-(Arg-Gly-Asp-D-Phe-Lys(BOC-Aha)), 及其鹽。 2. —種作為整合素抑制劑之醫藥組合物,其含有至少一種 根據申請專利範圍第1項之化合物及/或其生理可接受鹽 類。 3. 根據申請專利範圍第1項之化合物,其係作為整合素抑 制劑,以控制病理性血管生成障礙,血栓,心肌梗塞, 冠狀心臟病,動脈硬化,腫瘤,骨質疏鬆症,發炎或感 染。 4. 根據申請專利範圍第1項之化合物,係用於藉親和力色 析法以純化整合素。 5. 根據申請專利範圍第1項之化合物,係用於ELISA-型分 析及FACS分析中做為抗-生物素抗體反應診斷標識劑, 但該化合物不為環-(Arg-Gly-Asp-D-Phe-Lys(Ns-Aha))或環 -(Arg-Gly-Asp-D-Phe-Lys(BOC-Aha))。 6. 根據申請專利範圍第1項之化合物,係用於力場顯微鏡 術中測定配位體-受體交互作用強度。 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 裝 訂 參 517063 产yf) /j 第85108686號專利申請案 >' 中文補充說明書1(八十九年二月) 實例1 Bit-Gly-Gly-Gly-Arg-Gly-Asp-Ser-Pro-Lys-OH x 2 TFA IR [cm·1]: 3374 v(N-H),醯胺,尿素,呱啶 2941 v (C-H),脂族 2850 (sh) v(C-H),脂族 2500-3200 (br) v (O-H),COOH 1670 v (C=0),醯胺(疊加醯胺基團, COOH) 1539 醯胺II 1452 5(CH2)? 實例2 Bit-Gly-Gly-Gly-Lys-Thr-Ala-Asp-Cys (Trt)-Pro-OH x 2 TFA IR [cm·1]: 3400-3300 v(N-H),醯胺,尿素 2932 v(C-H),醯胺 2850 (sh) v(C-H),月旨族 2500-3200 (br) v (O-H),COOH 1725 (sh) v (C=0),COOH 1653 v (C=0),醯胺(疊加9醯胺基團) 1532 醯胺II 1446 6(CH2)? 703, 744 單取代芳族 _ 實例3 環-(Arg-Gly-Asp-D-Phe-Lys (Ne-Bit)) x 2 TFA P:\PTS\RF\ATYPE\B\2463G-1 DOC\2\en 517063 IR [cm'1]: 3417 v(N-H),狐症 3300 v (N-H),醯胺,尿素 2938 v(C-H),脂族 2850 v(C-H),脂族 2500-3200 (br) v (O-H), COOH 1700 (sh) v (C=0),COOH 1670 v(OO),尿素 1545 醯胺II 1456 6(CH2)5 703, 722 單取代芳族 實例5 IR [cm-1]: 3410 v(N-H),p瓜咬 3284 v(N-H),醯胺 2937 v(C-H),脂族 2850 v(C-H),月旨族 2500-3200 (br) v (O-H),COOH 1640 v (00),醯胺(疊加6醯胺基團) 1548 醯胺II 1436 δ (ch2), 701,722 單取代芳族 P:\PTS\RF\ATYPE\B\2463G-1 ,D〇C\2\en -2- 517063 實例6 IR [cm'1]: 3428 v (N-H),狐淀 3295 v(N-H),醯胺,尿素 2929 v (C-H),脂族 2850 v (C-H),脂族 2500-3200 (br) v (O-H),COOH 1700 v (C=0),COOH 1680 (sh) v(C=0),尿素 1638 v (C=0),醯胺(疊加8醯胺基團) 1550 醯胺II 1454 δ (ch2), 700, 722 單取代芳族 實例6 環-(Arg-Gly-Asp-D-Phe-Val-Lys (Ne-Bit-Aha))) X TFA IR [cm'1]: 3416 v(N-H),呱啶 3300 v(N-H),醯胺,尿素 2932 v (C-H),脂族 2850 v(C-H),脂族 2500-3200 (br) v (O-H),COOH 1700 (sh) v (C=0),COOH 1680 (sh) v(C=0),尿素 1652 v (C=0),疏胺(疊加8醯胺基團) 1540 醯胺II - 1457 δ (CH2), 700, 722 單取代芳族 P:\PTS\RFUTYPE\B\2463G-1 DOC\2\en -3- 517063 實例4 IR [cm-1]: 3400 (sh) v (N-H),狐淀 3289 v(N-H),醯胺,尿素 2933 v(C»H),月旨族 2850 v(C-H),脂族 2500-3200 (br) v (O-H),COOH 1700 (sh) v (C=0),COOH 1680 (sh) v(C=0),尿素 1642 v(c=o),酿胺(疊力口 7 si胺基團) 1549 醯胺II 1437 δ(〇Η2), 700, 730 單取代芳族 實例5 環-(Arg-Gly-Asp-D-Phe-Lys (BOC_Aha)) X TFA IR [cm'1]: 3416 v(N-H),呱啶 3300 (sh) v(N-H),醯胺 2927 v(C-H),月旨族 2850 v (C-H),脂族 2500-3200 (br) v (O-H), COOH 1725 (sh) v (C=0),COOH 1680 (sh) v(C=0),胺甲酸酉旨 1640 v (C=0),酿胺(疊加7酿胺基團) 1543 醯胺II 1454 δ (ch2), - 1397,1391 3(CH3),第三丁基 698 芳族 P:\PTS\RF\ATYPE\B\2463G-I.DOC\2\en -4- 第851〇8686號專利申請案 中文補充說明書II (八+九年二月) 受體抑制分析 使衍生自血小板之純化人類整合素GPIIbllla(即cxllbp3)及衍生自胎盤 之αγβ3吸附於微滴定盤小孔中,在增加量之受試化合物存在下,以生 物素化之互補配體vitrovectin (VN)激化αγβ3,且以血纖維蛋白原 (FGN)激化αΙΠ^β3。 方法·在系序稀釋之胜肤存在下,使1 pg mr1之生物素-配體與 1 pg ml·1之經包覆受體共培養。在30它下培養3小時後,以 抗生物素-械性磷脂酶方法量測經結合之配體。 參考文獻:Charo, I.F·,Nannizzi,L_,Smith,J.W. and Cheresh,D.A” J· Cell· Biol. 111,2795-2800 (1990)· 表I生物素化配體與人類胎盤αγβ3及血小板anbp3結合之汇50值 序列 IC5〇 [nM] VN: ανβ3 IC5〇 [nM] FGN:aIIbR^ Gly-Arg-Gly-Asp-Ser-Pro-Lys (Noiri et al., kidney International (1994)) 1750 5380 2.2 983 環-(Arg-Gly-Asp-D-Phe-Lys (Ne-Aha)) 2 600 6 1900 2.2 983 2 600 在兩種分析系統中,與比較化合物相較,受試化合物對於與 vitrovectin之交互反應及對allbp3與血纖維蛋白原之交互反應,均顯 示較強之抑制活性。 _ P:\PTS\RF\ATYPE\B\2463G-1 DOC\3\en
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19534016A DE19534016A1 (de) | 1995-09-14 | 1995-09-14 | Biotinderivate |
Publications (1)
Publication Number | Publication Date |
---|---|
TW517063B true TW517063B (en) | 2003-01-11 |
Family
ID=7772112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW085108686A TW517063B (en) | 1995-09-14 | 1996-07-17 | Biotin derivatives |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP0771818B1 (zh) |
JP (1) | JP4127325B2 (zh) |
KR (1) | KR970015597A (zh) |
CN (1) | CN1168738C (zh) |
AT (1) | ATE215558T1 (zh) |
AU (1) | AU719307B2 (zh) |
BR (1) | BR9603741A (zh) |
CA (1) | CA2185394C (zh) |
CZ (1) | CZ291506B6 (zh) |
DE (2) | DE19534016A1 (zh) |
DK (1) | DK0771818T3 (zh) |
ES (1) | ES2174007T3 (zh) |
HU (1) | HUP9602223A3 (zh) |
MX (1) | MX9604019A (zh) |
NO (1) | NO314694B1 (zh) |
PL (1) | PL316069A1 (zh) |
PT (1) | PT771818E (zh) |
RU (1) | RU2171807C2 (zh) |
SI (1) | SI0771818T1 (zh) |
SK (1) | SK283129B6 (zh) |
TW (1) | TW517063B (zh) |
UA (1) | UA41981C2 (zh) |
ZA (1) | ZA967765B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113827591A (zh) * | 2021-11-09 | 2021-12-24 | 上海市肺科医院 | 生物素在制备治疗脓毒症药物中的应用 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000038730A2 (en) | 1998-12-23 | 2000-07-06 | G.D. Searle & Co. | Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia |
US20010053766A1 (en) * | 2000-02-11 | 2001-12-20 | Janardan Kumar | Method of treating disorders of the eye |
KR100778633B1 (ko) * | 2007-04-13 | 2007-11-28 | 성균관대학교산학협력단 | 비오틴과 비오틴-폴리에틸렌글리콜이 접합된 glp-1유도체, 이의 제조방법 및 이를 포함하는 약학 조성물 |
EP2259768B1 (en) * | 2008-04-08 | 2019-05-22 | Merck Patent GmbH | Compositions containing cyclic peptides and methods of use |
CN108956790A (zh) * | 2017-05-18 | 2018-12-07 | 中国人民解放军第二军医大学第二附属医院 | 一组氨基酸标志物在急性肾损伤诊断试剂盒中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5315076B2 (zh) * | 1973-09-27 | 1978-05-22 | ||
JP2945680B2 (ja) * | 1988-09-09 | 1999-09-06 | 旭硝子株式会社 | ペプチド誘導体およびその用途 |
US5087561A (en) * | 1990-06-28 | 1992-02-11 | Merck & Co., Inc. | Humoral hypercalcemic factor antagonists modified at position 13 by biotin |
DE4310643A1 (de) * | 1993-04-01 | 1994-10-06 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
US5462939A (en) * | 1993-05-07 | 1995-10-31 | Sterling Winthrop Inc. | Peptidic ketones as interleukin-1β-converting enzyme inhibitors |
DE4336758A1 (de) * | 1993-10-28 | 1995-05-04 | Merck Patent Gmbh | Lineare Adhäsionsinhibitoren |
-
1995
- 1995-09-14 DE DE19534016A patent/DE19534016A1/de not_active Withdrawn
-
1996
- 1996-07-17 TW TW085108686A patent/TW517063B/zh not_active IP Right Cessation
- 1996-08-13 HU HU9602223A patent/HUP9602223A3/hu unknown
- 1996-09-09 CZ CZ19962629A patent/CZ291506B6/cs not_active IP Right Cessation
- 1996-09-09 AU AU65518/96A patent/AU719307B2/en not_active Ceased
- 1996-09-10 DK DK96114454T patent/DK0771818T3/da active
- 1996-09-10 AT AT96114454T patent/ATE215558T1/de active
- 1996-09-10 DE DE59608995T patent/DE59608995D1/de not_active Expired - Lifetime
- 1996-09-10 PT PT96114454T patent/PT771818E/pt unknown
- 1996-09-10 SK SK1156-96A patent/SK283129B6/sk unknown
- 1996-09-10 SI SI9630482T patent/SI0771818T1/xx unknown
- 1996-09-10 EP EP96114454A patent/EP0771818B1/de not_active Expired - Lifetime
- 1996-09-10 ES ES96114454T patent/ES2174007T3/es not_active Expired - Lifetime
- 1996-09-11 MX MX9604019A patent/MX9604019A/es not_active IP Right Cessation
- 1996-09-12 BR BR9603741A patent/BR9603741A/pt active Search and Examination
- 1996-09-12 CN CNB961125985A patent/CN1168738C/zh not_active Expired - Fee Related
- 1996-09-12 CA CA002185394A patent/CA2185394C/en not_active Expired - Fee Related
- 1996-09-13 KR KR1019960039768A patent/KR970015597A/ko not_active Application Discontinuation
- 1996-09-13 UA UA96093556A patent/UA41981C2/uk unknown
- 1996-09-13 RU RU96118231/04A patent/RU2171807C2/ru not_active IP Right Cessation
- 1996-09-13 ZA ZA967765A patent/ZA967765B/xx unknown
- 1996-09-13 JP JP26372696A patent/JP4127325B2/ja not_active Expired - Fee Related
- 1996-09-13 PL PL96316069A patent/PL316069A1/xx unknown
- 1996-09-13 NO NO19963851A patent/NO314694B1/no unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113827591A (zh) * | 2021-11-09 | 2021-12-24 | 上海市肺科医院 | 生物素在制备治疗脓毒症药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CA2185394A1 (en) | 1997-03-15 |
EP0771818B1 (de) | 2002-04-03 |
DE19534016A1 (de) | 1997-03-20 |
AU6551896A (en) | 1997-03-20 |
AU719307B2 (en) | 2000-05-04 |
BR9603741A (pt) | 1998-06-02 |
EP0771818A3 (de) | 1997-07-02 |
CN1153784A (zh) | 1997-07-09 |
NO963851D0 (no) | 1996-09-13 |
SI0771818T1 (en) | 2002-10-31 |
DE59608995D1 (de) | 2002-05-08 |
CN1168738C (zh) | 2004-09-29 |
MX9604019A (es) | 1997-03-29 |
ATE215558T1 (de) | 2002-04-15 |
PT771818E (pt) | 2002-09-30 |
UA41981C2 (uk) | 2001-10-15 |
EP0771818A2 (de) | 1997-05-07 |
ZA967765B (en) | 1997-03-26 |
DK0771818T3 (da) | 2002-07-29 |
JPH09124692A (ja) | 1997-05-13 |
PL316069A1 (en) | 1997-03-17 |
HU9602223D0 (en) | 1996-10-28 |
JP4127325B2 (ja) | 2008-07-30 |
CA2185394C (en) | 2007-05-01 |
RU2171807C2 (ru) | 2001-08-10 |
ES2174007T3 (es) | 2002-11-01 |
KR970015597A (ko) | 1997-04-28 |
CZ262996A3 (cs) | 1998-02-18 |
HUP9602223A2 (en) | 1997-06-30 |
HUP9602223A3 (en) | 1998-03-02 |
NO314694B1 (no) | 2003-05-05 |
SK283129B6 (sk) | 2003-02-04 |
CZ291506B6 (cs) | 2003-03-12 |
SK115696A3 (en) | 1997-05-07 |
NO963851L (no) | 1997-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Garanger et al. | Multivalent RGD synthetic peptides as potent α V β 3 integrin ligands | |
JP5358564B2 (ja) | 環状ペプチドcxcr4アンタゴニスト | |
ES2404052T3 (es) | Péptidos que tienen actividad farmacológica para el tratamiento de trastornos asociados con la migración celular alterada, tal como el cáncer | |
TWI247748B (en) | Peptide antiangiogenic drugs | |
CN102741269B (zh) | Gadd45β靶向剂 | |
JP4786047B2 (ja) | ペプチド誘導体 | |
McElroy et al. | Highly potent and selective heptapeptide antagonists of the neurokinin NK-2 receptor | |
JPH10506608A (ja) | 白血球接着のインヒビター | |
JPH09509142A (ja) | 新規のインテグリン結合ペプチド | |
BRPI0717441B1 (pt) | Composto, medicamento, e, uso do derivado de metastina | |
JP2008540340A (ja) | カドヘリン介在過程を調節する化合物及び方法 | |
US11510991B2 (en) | Polypeptide conjugates for intracellular delivery of stapled peptides | |
KR100286242B1 (ko) | 돌라스타틴 유도체 | |
JP2000512277A (ja) | ペプチド誘導体 | |
TWI226890B (en) | Cyclic peptide derivatives as inhibitors of integrin alphavbeta6 | |
CZ20013318A3 (cs) | Noví LH-RH-antagonisté se zlepąenými vlastnostmi rozpustnosti | |
CA2343924A1 (en) | Peptide derivative | |
AU641366B2 (en) | Peptide compounds | |
TW517063B (en) | Biotin derivatives | |
AU2004253475A1 (en) | Leukocyte internalized peptide-drug conjugates | |
JP2001514659A (ja) | ドラスタチン−15誘導体とタキサンとの併用 | |
CN102325540A (zh) | 具有至少一个合成的氨基酸替换的神经肽y的类似物 | |
CZ20014484A3 (cs) | Inhibitory integrinu alfa v beta 6 | |
WO1999065944A1 (en) | PEPTIDE INHIBITORS OF αVβ3 AND αVβ¿5? | |
KR20010101178A (ko) | αvβ6 인테그린 저해제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MM4A | Annulment or lapse of patent due to non-payment of fees |